vaccin
alan
r
shaw
vaccin
repres
one
effect
costeffect
medic
public
health
achiev
time
worldwid
vaccin
program
current
estim
save
million
live
year
addit
major
benefici
impact
vaccineprevent
diseas
morbid
mortal
direct
indirect
impact
vaccin
program
translat
econom
save
mani
billion
dollar
year
consid
one
histori
signific
medic
success
collabor
comprehens
vaccin
campaign
smallpox
result
global
erad
diseas
similarli
effort
erad
poliomyel
made
tremend
progress
reduc
global
diseas
burden
hope
soon
overcom
certain
residu
societ
programmat
obstacl
provid
second
success
exampl
elimin
major
health
threat
vaccin
concert
global
effort
provid
measl
vaccin
result
control
elimin
diseas
mani
countri
includ
substanti
reduct
mortal
number
develop
countri
residu
diseas
burden
greatest
exampl
provid
clear
evid
power
vaccin
favor
manipul
host
immun
confer
dramat
public
health
benefit
individu
popul
level
vaccin
administ
healthi
individu
often
entir
age
cohort
popul
prevent
diseas
caus
infecti
agent
might
expos
futur
thu
differ
import
way
pharmacolog
agent
use
treat
individu
diseas
process
alreadi
manifest
display
predisposit
diseas
reason
vaccin
uniqu
way
impact
societi
way
societ
commit
vaccin
determin
ultim
impact
result
vaccin
effort
provid
inform
window
challeng
need
success
navig
interfac
scientif
opportun
societ
capac
commit
inde
current
limit
realiz
full
global
potenti
avail
vaccin
relat
exist
inadequaci
health
care
financ
infrastructur
especi
manifest
develop
countri
rel
valu
societi
place
diseas
prevent
inher
biolog
limit
vaccin
follow
initi
expand
programm
immun
epi
global
coverag
routin
vaccin
three
dose
diphtheriatetanuspertussi
vaccin
progress
increas
mani
children
resourcelimit
countri
still
fail
receiv
recommend
childhood
immun
fortun
recent
acceler
new
vaccin
introduct
develop
countri
public
privat
initi
gavi
allianc
unicef
build
immun
infrastructur
provid
fund
vaccin
purchas
includ
novel
fund
mechan
vaccin
procur
advanc
market
commit
amc
pneumococc
conjug
vaccin
intern
financ
facil
immun
iffim
offer
hope
vaccin
one
day
equit
avail
need
achiev
aspir
repres
focu
recent
launch
initi
refer
decad
vaccin
collabor
http
wwwdovcollaborationorg
import
vaccin
extend
beyond
use
public
health
tool
includ
role
driver
immunolog
discoveri
histori
vaccin
develop
rich
immunolog
insight
emerg
care
observ
diseas
spread
popul
spread
differ
experienc
popul
well
innov
experiment
approach
reveal
fundament
aspect
immun
system
function
gener
concept
immun
induc
prior
exposur
diseas
includ
specif
potenti
lifelong
durat
appreci
ancient
greek
use
word
immun
context
human
health
date
fourteenth
centuri
appli
describ
rel
suscept
resist
popul
plagu
subsequ
success
edward
jenner
loui
pasteur
develop
effect
smallpox
fowl
cholera
immun
strategi
respect
provid
foundat
modern
immunolog
pasteur
coin
term
vaccin
recognit
jenner
use
vaccinia
viru
jenner
smallpox
immun
studi
also
provid
earli
experiment
support
concept
immun
memori
pasteur
effort
provid
first
demonstr
attenu
pathogen
propag
cultur
passag
nonnatur
anim
host
robert
koch
demonstr
kill
pathogen
could
also
engend
immun
discoveri
bacteri
exotoxin
emil
roux
alexandr
yersin
facilit
discoveri
antibodi
potenti
use
passiv
immunotherapi
antitoxin
antibodi
emil
von
behr
shibasaburo
kitasato
discoveri
enabl
develop
activ
immun
diphtheria
tetanu
use
toxinantitoxin
mixtur
paul
ehrlich
develop
accur
method
antibodi
quantit
made
passiv
immunotherapi
activ
toxinantitoxin
immun
far
reliabl
effect
provid
stimulu
signific
advanc
immunolog
theori
instanc
vaccin
develop
illumin
central
mechan
immun
system
biolog
vaccin
develop
today
transit
approach
larg
empir
one
base
hypothesisdriven
applic
techniqu
molecular
biolog
immunolog
evid
synergi
seen
recent
studi
vaccineelicit
immun
respons
illumin
elsevi
ltd
determin
activ
innat
immun
respons
determin
magnitud
persist
primari
memori
tand
bcell
respons
human
also
provid
strong
discoveri
stimulu
provid
ongo
effort
develop
new
vaccin
major
infecti
diseas
vaccin
current
avail
vaccin
develop
today
face
number
signific
challeng
exist
tremend
public
health
need
address
major
wellknown
pandem
diseas
includ
acquir
immunodefici
syndrom
aid
tuberculosi
malaria
effect
vaccin
current
exist
natur
immun
provid
help
guid
vaccin
develop
furthermor
exist
need
confront
effect
newli
emerg
reemerg
diseas
rang
wellknown
constantli
chang
threat
influenza
pandem
appear
previous
unknown
zoonot
infect
coronaviru
caus
sever
acut
respiratori
syndrom
sar
chang
popul
densiti
mobil
social
construct
along
alter
global
climat
ecolog
circumst
proxim
human
anim
reservoir
previous
confin
infecti
agent
concept
new
infecti
agent
enter
human
popul
spread
rapidli
around
world
longer
novel
confront
preval
newli
emerg
diseas
vaccin
look
promis
line
defens
howev
speed
new
infecti
diseas
threat
emerg
spread
fact
pathogen
need
confront
may
display
tremend
genet
variabl
eg
human
immunodefici
viru
hiv
ident
predict
advanc
eg
avian
influenza
emerg
zoonot
infecti
agent
like
sar
coronaviru
place
unpreced
demand
vaccin
develop
process
addit
new
challeng
remain
unmet
need
deriv
vaccin
achiev
greatest
public
health
benefit
need
includ
develop
new
way
achiev
effect
vaccineelicit
immun
respons
neonat
whose
immun
system
immatur
impact
matern
antibodi
chapter
elderli
whose
immun
system
function
may
wane
result
immun
senesc
chapter
fortun
scientif
foundat
provid
basic
appli
immunolog
use
new
method
pathogen
identif
antigen
discoveri
vaccin
product
adjuv
develop
novel
vector
deriv
afford
import
opportun
vaccin
develop
addit
present
possibl
improv
natur
immun
success
vaccin
develop
predic
continu
histor
synergi
advanc
vaccin
technolog
basic
immunolog
discoveri
toward
end
chapter
focus
prevent
vaccin
infecti
diseas
develop
although
current
routin
vaccin
recommend
review
given
activ
state
new
vaccin
introduct
evolv
vaccin
recommend
well
differ
recommend
differ
countri
reader
encourag
refer
uptod
nation
resourc
current
inform
vaccin
approach
also
activ
explor
treat
specif
malign
immunolog
diseas
autoimmun
allergi
beyond
scope
current
discuss
unlik
medic
intervent
vaccin
confer
benefit
individu
popul
individu
protect
infect
diseas
vaccineinduc
immun
respons
decreas
number
suscept
host
popul
also
help
break
chain
transmiss
pathogen
requir
spread
persist
human
popul
induct
herd
immun
benefit
herd
immun
depend
achiev
suffici
high
immun
rate
popul
impact
pathogen
transmiss
dynam
includ
potenti
extinct
ongo
interhost
transmiss
requisit
level
vaccin
coverag
popul
need
compromis
pathogen
spread
significantli
vari
pathogen
influenc
vaccin
efficaci
durat
reproduct
characterist
infecti
pathogen
analysi
impact
vaccin
program
usa
provid
exampl
benefici
impact
vaccin
use
routin
high
coverag
level
achiev
numer
vaccin
target
import
infecti
diseas
develop
sinc
tetanu
toxoidth
first
vaccin
licens
usawa
introduc
vaccin
introduc
routin
vaccin
program
usa
annual
morbid
mani
vaccineprevent
diseas
dramat
decreas
tabl
mani
instanc
diseas
burden
sever
vaccineprevent
diseas
childhood
reduc
sinc
vaccin
introduct
eg
diphtheria
tetanu
measl
mump
rubella
polio
somewhat
lower
rate
declin
pertussi
annual
morbid
reduc
nonetheless
impress
relat
limit
durat
vaccineinduc
immun
estim
wane
within
year
childhood
vaccin
anticip
recent
avail
pertussi
booster
vaccin
use
adolesc
adult
lead
signific
declin
pertussi
morbid
even
diseas
target
vaccin
widespread
use
less
time
impress
decreas
diseas
morbid
seen
eg
varicella
hepat
pneumococc
rotaviru
diseas
notabl
recent
demonstr
popul
benefit
vaccin
introduct
pneumococc
conjug
vaccin
result
decreas
rate
invas
pneumococc
diseas
ipd
children
year
age
within
first
year
introduct
infect
caus
antibioticresist
streptococcu
pneumonia
also
fall
dramat
age
group
strike
relat
find
illustr
vaccin
impact
pathogen
transmiss
dynam
ipd
rate
also
decreas
significantli
nonvaccin
children
well
individu
age
receiv
vaccin
thu
direct
protect
vaccin
children
repres
reservoir
infect
provid
via
herd
immun
signific
indirect
benefit
receiv
vaccin
anoth
manifest
impact
vaccin
dynam
pathogen
transmiss
rate
ipd
caus
serotyp
includ
especi
increas
remain
low
compar
decreas
ipd
address
dynam
provid
even
broader
protect
pneumococc
diseas
vaccin
higher
valenc
pcv
introduc
recent
addit
benefit
prevent
diseas
morbid
mortal
routin
vaccin
program
also
impress
costeffect
evalu
usa
impact
ten
vaccin
routin
given
part
childhood
immun
schedul
diphtheria
tetanu
pertussi
haemophilu
influenza
b
hib
polio
measl
mump
rubella
hepat
b
varicella
found
million
case
diseas
death
avert
lifetim
immun
birth
cohort
children
cost
vaccin
program
compar
econom
impact
diseas
prevent
vaccin
alon
estim
save
nearli
billion
year
includ
indirect
econom
benefit
time
parent
take
work
care
sick
children
annual
save
societi
exceed
billion
prevent
servic
rank
base
clinic
prevent
diseas
burden
costeffect
childhood
immun
receiv
highest
score
progress
develop
new
vaccin
acceler
significantli
toward
end
twentieth
centuri
develop
vaccin
diseas
previous
prevent
vaccin
also
develop
improv
version
exist
vaccin
thu
number
diseas
prevent
vaccin
includ
us
center
diseas
control
prevent
cdc
routin
childhood
adolesc
immun
schedul
grew
tabl
appendix
see
http
wwwcdcgovvaccinesdefaulthtm
expand
recommend
vaccin
children
adolesc
introduc
sinc
broader
use
quadrival
meningococc
conjug
vaccin
recommend
routin
use
quadrival
human
papilloma
viru
vaccin
male
number
target
diseas
remain
constant
age
group
moreov
past
sever
year
new
vaccin
introduc
adolesc
young
adult
eg
pertussi
booster
tdap
meningococc
conjug
human
papillomaviru
hpv
vaccin
older
adult
eg
tdap
zoster
vaccin
shown
valu
vaccin
extend
across
human
lifespan
new
combin
vaccin
develop
increas
simplic
accept
vaccin
regimen
well
improv
overal
complianc
recommend
seri
vaccin
combin
includ
either
contain
multipl
inactiv
recombin
antigen
combin
diphtheria
pertussi
tetanu
hib
hepat
b
vaccin
multipl
live
attenu
virus
combin
measl
mump
rubella
varicella
vaccin
mmrv
develop
combin
vaccin
often
complic
simpli
combin
individu
antigen
antigen
administ
combin
immunolog
interfer
sometim
seen
necessit
titrat
antigen
combin
case
combin
inactiv
andor
recombin
antigen
adjuv
select
achiev
immun
respons
inferior
antigen
administ
individu
despit
readili
demonstr
public
health
impact
valu
vaccin
often
appreci
vaccin
program
success
diseas
caus
becom
less
preval
may
disappear
howev
prevent
resurg
infecti
diseas
brought
control
vaccin
program
need
continu
difficulti
face
current
effort
erad
poliomyel
demonstr
failur
maintain
high
immun
coverag
rate
lead
prompt
reemerg
spread
diseas
even
develop
countri
mainten
strong
immun
program
high
degre
coverag
need
infecti
diseas
travel
remark
speedand
even
extent
spread
evid
h
e
r
p
e
u
c
p
r
n
c
p
l
e
special
attribut
vaccin
vaccin
benefit
individu
popul
vaccin
repres
one
effect
costeffect
public
health
innov
time
effect
vaccin
need
administ
target
cohort
individu
advanc
pathogen
exposur
vaccin
suffici
number
individu
popul
induct
herd
immun
impact
transmiss
dynam
pathogen
spread
popul
even
unimmun
individu
less
like
becom
infect
suffici
high
prolong
immun
coverag
depend
whether
nonhuman
reservoir
pathogen
persist
exist
possibl
erad
infecti
diseas
human
popul
accomplish
smallpox
pursu
polioviru
mani
contemporari
global
health
threat
eg
human
immunodefici
viru
hiv
tuberculosi
malaria
pandem
influenza
develop
effect
vaccin
consid
repres
promis
strategi
public
health
protect
unlik
drug
administ
individu
risk
specif
diseas
vaccin
commonli
administ
healthi
individu
result
risktobenefit
ratio
vaccin
requir
vaccin
meet
especi
high
standard
safeti
toler
term
vaccin
immun
often
use
interchang
howev
vaccin
specif
refer
effort
induc
protect
immun
respons
administr
vaccin
wherea
immun
gener
refer
interventionseith
activ
passivethat
seek
confer
immun
protect
activ
immun
describ
induct
immun
respons
administr
specif
antigen
antigen
passiv
immun
involv
administr
exogen
immunolog
activ
substanc
histor
antibodi
present
sera
obtain
immun
individu
anim
confer
temporari
protect
infecti
pathogen
toxin
although
approach
passiv
immun
wane
later
half
twentieth
centuri
advent
increas
robust
monoclon
antibodi
technolog
led
resurg
interest
passiv
immun
vaccin
seek
engend
immun
respons
similar
confer
immun
reinfect
individu
experi
surviv
natur
infect
given
pathogen
lieu
formal
demonstr
specif
type
antibodi
cellular
immun
respons
contribut
prevent
acceler
clearanc
infect
often
vaccin
efficaci
demonstr
first
cours
placebocontrol
trial
instanc
specif
immun
effector
mechan
specif
level
type
antibodi
respons
identifi
correl
immun
protect
case
correl
immun
provid
benchmark
similar
vaccin
compar
case
inactiv
vaccin
subunit
vaccin
recombin
vaccin
produc
antibodi
respons
gener
limit
tcell
respons
like
humor
immun
respons
primari
sole
protect
immun
mechan
case
live
attenu
vaccin
induc
cellular
humor
immun
respons
pathogen
like
arm
immun
system
act
concert
confer
immun
howev
actual
mechan
immun
protect
induc
either
natur
infect
vaccin
gener
understood
detail
mani
infecti
diseas
similarli
although
vaccin
depend
induct
immunolog
memori
magnitud
charact
durat
immun
memori
differ
vaccin
actual
mechan
immun
protect
certain
vaccin
protect
bacteri
diseas
induc
via
product
toxin
eg
diphtheria
tetanu
protect
induc
toxoidbas
vaccin
clearli
depend
persist
antibodi
igg
memori
bcell
respons
ensur
suffici
antitoxin
antibodi
present
time
toxin
exposur
inactiv
clear
toxin
case
longliv
protect
hepat
b
suffici
level
antibodi
achiev
initi
immun
period
even
host
may
time
lose
detect
level
antibodi
respons
remain
protect
instanc
given
rel
long
incub
period
hepat
b
memori
antivir
bcell
respons
induc
vaccin
activ
facilit
neutral
clearanc
infect
clinic
diseas
manifest
although
popularli
believ
vaccin
confer
protect
induc
steril
immun
wherein
infecti
agent
block
even
infect
one
cell
expos
hostthi
clearli
case
number
vaccin
exampl
inactiv
polioviru
live
attenu
rotaviru
vaccin
prevent
degre
local
replic
pathogen
counterpart
gastrointestin
tract
expos
host
howev
effect
prevent
clinic
diseas
case
polioviru
vaccin
mediat
elicit
antibodi
respons
block
dissemin
infect
central
nervou
system
case
rotaviru
yet
unidentifi
immun
effector
limit
local
viru
replic
signific
gastrointestin
damag
occur
follow
infect
advent
new
tool
system
biolog
studi
definit
illumin
determin
magnitud
durat
vaccineelicit
immun
respons
examin
pattern
global
gene
express
induc
vaccin
well
reveal
novel
correl
predict
later
develop
protect
immun
respons
repres
activ
promis
area
research
addit
provid
new
approach
elucid
natur
vaccinemedi
immun
protect
new
methodolog
alreadi
provid
window
much
improv
understand
immun
system
function
human
also
hope
facilit
develop
safe
effect
vaccin
diseas
hiv
tb
rsv
other
vaccin
current
avail
describ
major
type
vaccin
licens
use
includ
live
attenu
organ
kill
inactiv
organ
subunit
vaccin
consist
purifi
partial
purifi
compon
organ
subunit
vaccin
produc
recombin
dna
technolog
use
live
attenu
vaccin
date
back
earli
work
jenner
pasteur
smallpox
fowl
cholera
vaccin
respect
fundament
concept
live
attenu
part
ten
prevent
therapi
immunolog
diseas
vaccin
mimic
effect
host
immun
respons
follow
natur
infect
live
attenu
vaccin
current
use
deriv
propag
initi
pathogen
organ
cultur
cell
differ
nonhuman
speci
nonphysiolog
temperatur
prolong
period
drive
pathogen
evolut
cultur
select
variant
adapt
growth
heterolog
cell
type
ex
vivo
often
lead
deriv
pathogen
variant
grow
poorli
vivo
human
unabl
caus
clinic
symptom
vaccin
develop
via
approach
includ
use
prevent
number
viral
bacteri
infect
includ
yellow
fever
measl
mump
rubella
polio
sabin
vaccin
varicellazost
use
prevent
chickenpox
shingl
rotaviru
one
version
avail
vaccin
tuberculosi
cholera
recent
technolog
appli
live
attenu
vaccin
develop
includ
applic
revers
genet
strategi
fig
involv
genet
reassort
attenu
viral
variant
use
develop
polyval
live
attenu
vaccin
influenza
rotaviru
fig
live
attenu
vaccin
current
use
highli
efficaci
protect
frequent
durabl
efficaci
mani
live
attenu
vaccin
like
reflect
abil
attenu
vaccin
replic
within
vaccin
host
expos
immun
system
pathogenderiv
antigen
manner
close
resembl
natur
locat
effect
natur
infect
live
attenu
vaccin
replic
within
vaccin
individu
induc
cellular
humor
b
cell
effector
respons
immunolog
memori
addit
live
attenu
vaccin
like
activ
host
innat
system
manner
similar
pathogen
parent
provid
inher
adjuv
effect
augment
adapt
immun
respons
key
consider
develop
live
attenu
vaccin
relat
rel
balanc
abil
induc
suffici
immun
respons
vivo
confer
protect
often
associ
level
preserv
replic
abil
vivo
abil
caus
symptom
may
also
relat
extent
vivo
replic
effect
also
safe
welltoler
vaccin
need
strike
specif
balanc
level
attenu
level
immunogen
addit
depend
natur
number
genet
mutat
respons
attenu
phenotyp
potenti
risk
revers
pathogen
form
exist
certain
vaccin
live
attenu
vaccin
observ
problem
clinic
practicelik
attenu
mutat
suffici
numer
genet
stabl
one
vaccin
revers
pathogen
form
seen
involv
specif
compon
live
attenu
oral
polioviru
vaccin
opv
sabin
vaccin
instanc
vaccin
revers
wildtyp
shown
lead
rare
case
paralyt
polio
approxim
one
case
per
million
dose
administ
base
observ
elimin
endogen
polio
transmiss
mani
develop
countri
inactiv
polio
vaccin
ipv
salk
vaccin
substitut
opv
howev
light
favor
cost
benefit
ratio
high
degre
efficaci
eas
administr
opv
continu
mainstay
polio
vaccin
effort
develop
countri
yet
effort
erad
polio
continu
advanc
new
solut
polio
vaccin
need
develop
depend
current
avail
opv
revert
pathogen
form
low
frequenc
ipv
produc
inactiv
pathogen
poliovirus
strain
requir
high
level
biocontain
posterad
environ
vaccin
use
physic
chemic
method
kill
otherwis
inactiv
pathogen
organ
repres
second
major
approach
vaccin
product
case
treatment
chemic
agent
bpropiolacton
formaldehyd
use
elimin
pathogen
infect
approach
benefit
present
pathogen
antigen
repertoir
immun
system
immun
host
use
instanc
inactiv
pathogen
possess
constitu
would
confer
signific
toxic
vaccin
base
kill
pathogen
believ
exert
protect
effect
via
elicit
pathogenneutr
antibodi
induct
memori
bcell
respons
like
concert
tcell
memori
howev
inactiv
pathogen
accomplish
de
novo
synthesi
pathogenderiv
gene
product
antigenpres
cell
apc
typic
induc
tcell
respons
chapter
addit
kill
vaccin
gener
less
immunogen
live
attenu
vaccin
result
commonli
administ
adjuv
often
aluminium
salt
see
section
adjuv
augment
immunogen
number
viral
bacteri
vaccin
current
use
kill
inactiv
vaccin
includ
wholecel
bordetella
pertussi
vaccin
influenza
viru
rabi
viru
hepat
viru
vaccin
number
bacteria
produc
toxin
repres
major
pathogen
compon
respons
diseas
infect
human
exampl
includ
corynebacterium
diphtheria
clostridium
tetani
detoxifi
version
toxin
refer
toxoid
repres
purifi
compon
vaccin
prevent
diphtheria
tetanu
respect
toxoid
histor
produc
chemic
inactiv
toxin
recent
genet
inactiv
via
target
mutagenesi
employ
acellular
pertussi
vaccin
also
purifi
subunit
vaccin
compos
defin
set
protein
constitu
prepar
cultur
bordetella
pertussi
two
segment
virus
differ
genet
characterist
use
infect
one
cell
progeni
virus
mix
infect
carri
rang
mixtur
gene
two
parent
virus
use
either
genet
immunolog
screen
method
reassort
virus
carri
precis
gene
composit
interest
select
approach
recent
employ
gener
live
attenu
vaccin
rotaviru
influenza
viru
strategi
gener
pentaval
bovinehuman
reassort
rotaviru
vaccin
shown
rotavirus
segment
doublestrand
rna
genom
compris
independ
rna
element
outer
shell
viru
compris
two
protein
involv
cell
bind
entri
specifi
viral
serotyp
p
type
g
type
also
repres
target
virusneutr
antibodi
pentaval
bovinehuman
rotaviru
vaccin
gener
modifi
jennerian
approach
bovin
rotaviru
attenu
human
result
host
rang
restrict
serv
gene
donor
backbon
gene
segment
encod
four
common
human
rotaviru
g
type
well
one
common
p
type
deriv
individu
rotaviru
isol
reassort
via
process
cell
coinfect
subsequ
select
recombin
virus
desir
composit
bovin
human
gene
segment
analog
genet
reassort
approach
also
use
gener
live
attenu
influenza
vaccin
instanc
three
attenu
coldadapt
viral
strain
two
type
one
type
b
use
coinfect
tissu
cultur
recent
circul
wildtyp
influenza
strain
deriv
vaccin
strain
includ
two
relev
hemagglutinin
ha
neuraminidas
na
encod
gene
segment
admix
six
backbon
gene
attenu
master
donor
viru
use
annual
influenza
vaccin
part
ten
prevent
therapi
immunolog
diseas
mechan
immun
protect
confer
purifi
subunit
vaccin
antibodi
respons
elicit
vaccin
antibodi
direct
capsular
polysaccharid
present
encapsul
bacteria
also
confer
protect
immun
number
import
instanc
induc
antibodi
exert
opsonophagocyt
effect
promot
phagocytosi
antibodyco
bacteria
instanc
bactericid
effect
initi
success
vaccin
effort
streptococcu
pneumonia
neisseria
meningitidi
util
purifi
prepar
capsular
polysaccharid
although
purifi
polysaccharid
induc
protect
level
antibodi
respons
adult
poorli
immunogen
children
year
age
function
rel
immatur
immun
system
addit
tindepend
antibodi
respons
elicit
purifi
capsular
polysaccharid
less
durabl
produc
presenc
tcell
help
mean
augment
antibodi
respons
polysaccharid
antigen
young
children
facilit
persist
develop
conjug
vaccin
repres
import
advanc
approach
purifi
polysaccharid
chemic
conjug
carrier
protein
diphtheria
toxoid
outermembran
protein
complex
ompc
deriv
n
meningitidi
carrier
protein
augment
tcell
helper
respons
polysaccharid
antigen
enabl
elicit
durabl
protect
antibodi
respons
even
young
children
polysaccharideconjug
vaccin
produc
protect
haemophilu
influenza
b
streptococcu
pneumonia
n
meningitidi
infect
advent
recombin
dna
technolog
provid
transform
event
histori
vaccin
develop
addit
facilit
identif
express
pathogenderiv
protect
antigen
techniqu
develop
enabl
largescal
manufactur
vaccin
recombin
dna
technolog
provid
new
path
develop
vaccin
pathogen
hepat
b
viru
hbv
hpv
could
grown
cultur
addit
recombin
method
provid
potenti
deriv
even
safer
version
avail
vaccin
first
recombin
vaccin
develop
recombin
hepat
b
surfac
antigen
hbsag
prepar
yeast
develop
hope
avoid
safeti
concern
relat
plasmaderiv
hbsag
vaccin
knowledg
immun
sera
could
provid
protect
passiv
immun
host
purifi
inactiv
plasmaderiv
hbsag
vaccin
could
elicit
protect
antibodi
laid
groundwork
develop
recombin
vaccin
recombin
vaccin
combin
adjuv
aluminium
salt
elicit
favor
immun
respons
highli
efficaci
well
toleratedal
featur
recombin
vaccin
expect
deliv
second
recombin
vaccin
develop
target
prevent
borrelia
burgdorferi
infect
caus
lyme
diseas
base
purifi
recombin
version
ospa
protein
vaccin
although
confer
degre
efficaci
face
implement
challeng
wide
embrac
result
withdrawn
market
recent
recombin
technologyderiv
purifi
subunit
vaccin
develop
consist
viruslik
particl
vlp
selfassembl
protein
hpv
produc
isol
viral
protein
fig
protein
target
virusneutr
antibodi
vaccin
consist
mixtur
type
caus
case
cervic
cancer
caus
case
genit
wart
hpv
type
alon
highli
efficaci
well
toler
interestingli
hpv
vlp
induc
antibodi
respons
exceed
follow
natur
hpv
infect
light
success
power
versatil
recombin
antigen
product
method
major
proport
new
vaccin
develop
effort
involv
use
protein
subunit
vaccin
produc
recombin
technolog
vaccin
produc
method
depend
larg
exclus
induct
antibodi
individu
select
subset
pathogen
protein
number
protein
produc
isol
recombin
method
prophylact
hpv
vaccin
viruslik
particl
vlp
bioengin
protein
pentam
selfassembl
viruslik
particl
specif
instanc
vlp
produc
via
process
selfassembl
individu
viral
capsid
protein
produc
recombin
dna
method
cell
cultur
system
approach
number
attract
aspect
includ
abil
produc
vlp
accur
display
conform
correct
epitop
recogn
neutral
antibodi
absenc
pathogenderiv
nucleic
acid
addit
recombin
vlp
employ
deriv
safe
effect
vaccin
pathogen
hepat
b
viru
hbv
human
papillomaviru
hpv
grown
cultur
thu
refractori
standard
vaccin
approach
attenu
inactiv
gener
vlp
compris
newli
develop
hpv
vaccin
shown
hpv
protein
repres
major
capsid
protein
target
virusneutr
protect
antibodi
deriv
hpv
type
interest
eg
type
produc
via
recombin
method
appropri
condit
individu
bioengin
protein
first
selfassembl
pentam
vlp
compris
pentam
almost
ident
morpholog
antigen
infecti
hpv
viru
particl
vlp
prepar
individu
hpv
type
combin
specif
adjuv
prepar
final
vaccin
product
vaccin
observ
elicit
lower
immun
respons
natur
infect
live
attenu
vaccin
develop
use
adjuv
optim
recombin
vaccin
immunogen
repres
import
parallel
area
futur
explor
see
k
e
c
n
c
e
p
develop
new
vaccin
depend
converg
public
health
need
biolog
plausibl
practic
feasibl
vaccin
develop
program
influenc
multipl
consider
includ
major
unmet
medic
public
health
need
today
known
natur
histori
pathogen
mechan
infect
interest
immun
given
antigen
associ
protect
diseas
follow
reexposur
context
natur
infect
natur
immun
capabl
prevent
reinfect
follow
initi
infect
specif
host
immun
effector
mechan
eg
antibodi
cell
identifi
like
agent
correl
immun
protect
pathogen
grown
cultur
pathogen
caus
lifethreaten
diseas
attenu
version
viru
would
face
imposs
barrier
demonstr
safeti
specif
antigen
antigen
identifi
repres
target
protect
host
immun
respons
protect
immun
respons
mediat
antibodi
target
antigen
produc
scalabl
quantiti
form
mimic
nativ
structur
effect
elicit
antibodi
respons
block
key
function
role
target
molecul
pathogen
otherwis
lead
pathogen
clearanc
chosen
antigen
present
system
best
way
produc
larg
scale
effect
way
present
antigen
pathogen
interest
immun
system
antigen
interest
suffici
immunogen
augment
desir
immun
respons
conjug
specif
carrier
addit
adjuv
necessari
vaccin
potenti
safeti
concern
anticip
vaccin
question
attack
rate
infect
gener
popul
infect
occur
rel
rare
overal
popul
subset
popul
identifi
higher
risk
infect
acceler
achiev
statist
signific
protect
test
evalu
vaccin
immunogen
need
carri
clinic
sampl
obtain
particip
clinic
trial
measur
antibodi
titer
tcell
respons
pathogen
presenc
quantiti
pathogen
serotyp
paramet
peculiar
diseas
question
repres
primari
criteria
vaccin
effect
develop
valid
test
repres
essenti
compon
feasibl
success
vaccin
clinic
studi
necessari
prelud
clinic
evalu
candid
vaccin
human
extens
preclin
research
develop
activ
undertaken
establish
vaccin
candid
desir
properti
toward
end
number
key
issu
need
address
first
anim
studi
must
show
vaccin
candid
rais
desir
type
magnitud
immun
respons
infecti
agent
second
vaccin
need
protect
anim
death
diseas
appropri
challeng
model
feasibl
ideal
cours
studi
specif
type
level
immun
respons
refer
correl
immun
protect
identifi
third
vaccin
rel
free
seriou
discern
toxic
side
effect
anim
administ
rout
intend
human
fourth
necessari
demonstr
vaccin
produc
consist
manner
process
follow
current
good
manufactur
practic
cgmp
process
first
clinic
trial
materi
produc
http
wwwfdagovcbergdlnsindcgmppdf
even
preclin
studi
complet
vaccin
develop
typic
begin
initi
dialog
regulatori
author
food
drug
administr
fda
european
medicin
agenc
emea
set
expect
necessari
suffici
advanc
clinic
studi
human
http
wwwfdagovcbergenetherapi
phase
studi
primarili
focu
detail
assess
safeti
toler
vaccin
evalu
immunogen
also
frequent
conduct
gener
phase
studi
includ
fewer
healthi
volunt
divid
unequ
receiv
vaccin
placebo
vaccine
per
placebo
recipi
phase
studi
typic
employ
escal
dose
candid
vaccin
dose
rang
progress
increas
step
threeto
fivefold
often
use
blood
sampl
taken
prescrib
interv
analyz
laboratori
evid
potenti
toxic
well
evid
vaccineelicit
immun
respons
phase
studi
consid
success
demonstr
candid
vaccin
well
toler
identifi
immedi
safeti
concern
need
close
monitor
potenti
futur
clinic
studi
ideal
phase
studi
also
provid
initi
indic
optim
dose
level
number
dose
requir
phase
ii
studi
typic
includ
sever
hundr
thousand
volunt
random
vaccin
placebo
assum
two
gener
design
type
phase
iia
studi
provid
addit
safeti
data
larger
number
individu
intend
age
receiv
intend
vaccin
dose
repres
gener
popul
intend
vaccin
use
healthi
individu
includ
phase
studi
well
provid
addit
data
vaccin
immunogen
even
larger
phase
iib
studi
provid
addit
data
vaccin
safeti
immunogen
subject
gener
repres
vaccin
might
recommend
importantli
also
provid
first
opportun
address
answer
question
vaccin
work
human
size
phase
iib
studi
need
detect
signal
vaccin
efficaci
depend
attack
rate
infect
target
vaccin
phase
ii
studi
also
present
first
opportun
identifi
potenti
laboratori
immunolog
correl
protect
diseaseif
natur
prior
experi
alreadi
done
order
placebo
recipi
phase
ii
trial
must
experi
suffici
number
case
diseas
vaccin
recipi
need
exhibit
signific
evid
decreas
risk
infect
diseas
addit
immunolog
part
ten
prevent
therapi
immunolog
diseas
measur
vaccine
need
captur
relev
protect
immun
respons
eg
type
level
antibodi
andor
cellular
immun
respons
predict
protect
measur
suffici
precis
reliabl
laboratori
measur
immun
correl
clinic
protect
subsequ
refin
vaccin
adjuv
manufactur
process
regimen
may
assess
simpl
immunogen
studi
rather
repeat
efficaci
studi
efficaci
establish
vaccin
difficult
ethic
carri
doubleblind
placebocontrol
efficaci
studi
vaccin
shown
immunogen
well
toler
phase
ii
studi
advanc
pivot
phase
iii
studi
requir
vaccin
licensur
regulatori
author
phase
iii
studi
intend
expand
safeti
databas
larger
number
individu
repres
specif
popul
vaccin
ultim
use
establish
definit
evid
protect
efficaci
establish
clinic
consist
vaccin
made
process
run
facil
intend
licensur
commerci
http
typic
phase
iii
studi
includ
subject
blind
placebocontrol
design
size
trial
allow
identif
less
frequent
safeti
event
also
provid
opportun
captur
data
health
care
util
cost
impact
vaccin
paramet
new
vaccin
ultim
includ
vaccin
program
multipl
vaccin
may
administ
time
also
necessari
conduct
concomitantus
studi
develop
new
vaccin
must
show
new
vaccin
impact
immunogen
exist
vaccin
exist
vaccin
impact
immunogen
new
vaccin
contrast
drug
licensur
fda
primari
determin
new
product
implement
medic
practic
vaccin
use
usa
includ
addit
process
evalu
best
employ
new
vaccin
optim
implement
public
health
impact
us
cdc
respons
make
recommend
use
licens
vaccin
reli
advisori
committe
immun
practic
acip
guidanc
acip
consid
sever
aspect
addit
vaccin
safeti
efficaci
includ
anticip
costeffect
practic
feasibl
potenti
altern
vaccin
deploy
strategi
consider
new
vaccin
success
implement
clinic
practic
achiev
greatest
public
health
impact
cdc
receiv
review
accept
recommend
acip
http
wwwcdcgovvaccinesrecsacip
recommend
publish
final
offici
form
morbid
mortal
weekli
report
mmwr
http
wwwcdcgovvac
cinesdefaulthtm
gener
recommend
concern
vaccin
storag
handl
administr
well
vaccin
inform
statement
viss
explain
benefit
risk
recommend
vaccin
provid
vaccin
recipi
parent
guardian
also
found
cdc
websit
approach
develop
vaccin
recommend
european
union
eu
somewhat
complic
multipl
sovereign
countri
involv
present
vaccin
evalu
registr
central
procedur
european
medicin
agenc
http
wwwemaeuropaeu
committe
medicin
product
human
use
chmp
vaccin
review
countri
repres
eu
whole
ultim
regist
mutual
recognit
procedur
base
upon
endors
member
state
occasion
individu
countri
contrast
vaccin
polici
determin
member
countri
retain
nation
advisori
committe
respons
nation
recommend
result
signific
heterogen
vaccin
recommend
within
eu
mani
develop
middleincom
countri
lack
regulatori
infrastructur
technic
expertis
conduct
formal
review
new
vaccin
commonli
reli
assess
made
world
health
organ
prequalif
procedur
avail
http
wwwwhointvac
cinesdocu
document
prequalif
process
assess
candid
vaccin
manufactur
standard
qualiti
safeti
efficaci
well
overal
accept
procur
un
agenc
unicef
addit
role
relat
prequalif
process
strateg
advisori
group
expert
sage
provid
recommend
vaccin
use
inform
nation
polici
countri
lack
nation
vaccin
polici
bodi
recommend
immun
schedul
us
children
adolesc
adult
appendix
updat
annual
basi
access
http
wwwcdcgovvac
cinesdefaulthtm
http
wwwcdcgovniprecsadultschedulehtm
respect
recommend
adult
immun
schedul
includ
inform
concern
use
special
popul
health
care
worker
pregnant
women
individu
specif
condit
associ
alter
impair
immun
function
individu
congenit
acquir
immunodefici
syndrom
recipi
immunosuppress
therapi
malign
asplenia
liver
diseas
renal
diseas
reader
encourag
check
ensur
follow
current
recommend
recommend
concern
use
specif
vaccin
travel
countri
vaccineprevent
diseas
may
present
found
http
wwwcdcgovtravel
vaccinationshtm
pregnanc
registri
exist
number
vaccin
usa
contact
inform
found
http
www
fdagovscienceresearchspecialtopicswomenshealthresearch
health
care
profession
encourag
report
exposur
pregnant
women
appropri
registri
hbv
vaccin
hpv
vaccin
meningococc
vaccin
varicella
vaccin
unlik
drug
util
treat
individu
suffer
given
diseas
state
vaccin
administ
normal
healthi
infant
adolesc
adult
consequ
standard
safeti
toler
vaccin
set
high
level
develop
new
vaccin
grade
process
clinic
studi
employ
involv
increasingli
larger
number
volunt
typic
progress
individu
select
free
identifi
health
problem
select
repres
overal
vaccin
popul
vaccin
develop
phase
studi
reveal
evid
safeti
concern
desir
evid
immunogen
major
focu
seri
larger
random
doubleblind
phase
ii
placebocontrol
studi
conduct
explor
safeti
toler
vaccin
increasingli
vulner
popul
may
identifi
preexist
health
problem
asymptomat
abnorm
detect
screen
laboratori
studi
reflect
import
document
safeti
new
vaccin
phase
iii
studi
assess
safeti
efficaci
new
vaccin
typic
involv
larg
number
volunt
inde
result
need
provid
evid
safeti
common
size
phase
iii
trial
significantli
larger
would
necessari
document
vaccin
efficaci
abil
studi
identifi
increas
risk
given
advers
event
suffici
statist
power
directli
relat
size
popul
studi
gener
rule
studi
subject
need
measur
risk
event
happen
one
individu
one
event
subject
need
even
studi
size
rare
event
may
identifi
specif
safeti
concern
exist
substanti
larger
trial
may
need
recent
experi
develop
rotaviru
vaccin
provid
illustr
exampl
import
place
document
vaccin
safeti
rotaviru
import
caus
seriou
gastroenter
infant
young
children
associ
diarrhea
vomit
lead
lifethreaten
dehydr
develop
countri
health
care
resourc
effect
rehydr
option
limit
infant
die
rotaviru
gastroenter
year
given
global
import
rotaviru
gastroenter
first
licensur
oral
administ
rotaviru
vaccin
welcom
advanc
howev
vaccin
enter
routin
pediatr
practic
recogn
low
increas
incid
intestin
intussuscept
seen
first
second
dose
one
case
intussuscept
seen
per
vaccine
upon
recognit
associ
vaccin
withdrawn
market
evid
public
health
need
safe
effect
rotaviru
vaccin
hope
altern
rotaviru
vaccin
develop
oral
vaccin
base
either
combin
bovinehuman
reassort
virus
fig
attenu
human
rotaviru
strain
might
differ
first
licens
rotaviru
vaccin
result
increas
rate
intussuscept
howev
demonstr
altern
rotaviru
vaccin
safe
increas
risk
intussuscept
inher
rotaviru
vaccin
class
largescal
safeti
studi
requir
toward
end
safeti
vaccin
evalu
studi
involv
infantsjust
evalu
whether
rate
intussuscept
vaccine
discern
increas
compar
normal
background
rate
seen
placebo
recipi
fortun
vaccin
found
well
toler
increas
intussuscept
observ
vaccin
compar
placebo
recipi
light
document
efficaci
vaccin
determin
earlier
significantli
smaller
phase
iii
trial
licens
number
countri
howev
even
larg
phase
iii
studi
conduct
newer
rotaviru
vaccin
continu
studi
larg
postlicensur
activ
surveil
safeti
studi
close
monitor
activ
passiv
vaccin
safeti
surveil
system
see
follow
vaccin
licensur
safeti
track
via
number
mean
includ
activ
passiv
surveil
studi
advers
event
activ
surveil
includ
phase
iv
postmarket
studi
vaccin
safeti
larger
popul
realworld
use
formal
postmarket
studi
includ
ten
thousand
individu
altern
type
postmarket
safeti
monitor
carri
us
fda
cdc
within
context
vaccin
advers
event
report
system
vaer
databas
http
wwwvaershhsgov
telephon
vaer
databas
accept
spontan
report
advers
experi
health
care
provid
patient
parent
vaccin
manufactur
sourc
best
use
vaer
databas
identifi
signal
popul
may
appear
follow
introduct
new
vaccin
newer
vaccin
safeti
surveil
system
known
vaccin
safeti
databas
vsd
develop
cdc
cooper
seven
larg
health
mainten
organ
hmo
around
usa
vsd
contain
complet
medic
record
member
particip
hmo
inform
use
popul
databas
enter
health
care
profession
use
rel
consist
terminolog
improv
qualiti
uniform
use
data
particularli
import
vsd
construct
allow
comprehens
epidemiolog
analys
determin
incid
rate
specif
advers
event
higher
among
vaccine
nonvaccine
addit
vaer
vsd
cdc
also
creat
clinic
immun
safeti
assess
network
review
pattern
clinic
syndrom
may
follow
vaccin
safeti
profil
vaccin
rel
well
defin
effort
describ
confid
vaccin
program
often
challeng
public
percept
either
real
unsubstanti
vaccin
safeti
instanc
specif
vaccin
associ
increas
incid
specif
advers
experi
associ
firstgener
rotaviru
vaccin
increas
risk
intussuscept
follow
vaccin
howev
number
safeti
concern
emerg
support
scientif
evid
exampl
found
case
concern
associ
wholecel
pertussi
vaccin
perman
brain
damageconcern
later
shown
unfound
nevertheless
public
concern
safeti
wholecel
pertussi
vaccin
result
decreas
level
pertussi
vaccin
coverag
soon
follow
epidem
whoop
cough
uk
japan
anoth
exampl
alleg
certain
vaccin
combin
measl
mump
rubella
mmr
vaccin
associ
autism
highlight
percept
tempor
associ
give
rise
public
concern
mmr
vaccin
gener
given
around
year
age
autism
gener
diagnos
second
year
life
although
alleg
causal
associ
mmr
autism
refut
multipl
extens
scientif
analys
report
popular
media
uk
result
dramat
drop
vaccin
rate
follow
increas
rate
new
infect
origin
public
lancet
subsequ
disavow
major
manuscript
author
formal
retract
lancet
editor
result
factual
misrepresent
ethic
violat
purport
associ
mmr
autism
thoroughli
discredit
claim
result
decreas
mmr
vaccin
rate
number
countri
result
parent
delay
refus
measl
vaccin
increas
number
geograph
cluster
unvaccin
children
rate
endem
measl
infect
recent
increas
sever
countri
europ
spillov
effect
nearli
rare
case
measl
report
usa
origin
us
travel
visit
endem
countri
immigr
vaccin
yet
avail
although
impress
armamentarium
vaccin
avail
safe
effect
vaccin
yet
develop
number
import
infecti
diseas
reason
underli
lack
effect
vaccin
array
import
pathogen
includ
biolog
consider
safeti
concern
practic
constraint
biolog
consider
often
import
barrier
discuss
vaccin
success
develop
pathogen
whose
natur
infect
give
rise
natur
immun
wherein
infect
host
least
surviv
initi
infect
longer
suscept
reinfect
measl
yellow
fever
viru
smallpox
experi
significantli
less
sever
clinic
sequela
upon
reinfect
rotaviru
instanc
natur
immun
follow
natur
infect
preced
immun
protect
establish
natur
protect
host
respons
studi
provid
correl
protect
guid
vaccin
develop
effort
howev
mani
pathogen
vaccin
remain
elus
natur
immun
follow
natur
infect
absenc
natur
immun
preced
success
immun
contain
lack
potenti
correl
protect
avail
inform
vaccin
develop
instanc
natur
immun
follow
natur
infect
persist
infect
establish
maintain
activ
viru
replic
control
clear
host
immun
respons
hiv
hepat
c
altern
pathogen
abl
persist
host
establish
via
divers
mechan
latent
infect
resist
host
immun
clearanc
tuberculosi
herp
virus
eg
herp
simplex
viru
hsv
epsteinbarr
viru
ebv
instanc
even
host
clear
infect
via
drug
treatment
host
remain
suscept
reinfect
diseas
futur
eg
malaria
although
differ
pathogen
evolv
divers
strategi
evas
host
immun
responsesrang
manifest
tremend
genet
divers
propens
immun
escap
sequestr
critic
structur
domain
might
suscept
antibodi
neutral
util
specif
mechan
evad
host
innat
adapt
immun
effectorsth
common
end
result
frustrat
vaccin
develop
failur
host
clearanc
infect
common
theme
underli
lack
vaccin
addit
obstacl
vaccin
develop
includ
immunolog
relat
consider
well
practic
safeti
consider
exampl
immunolog
relat
obstacl
includ
instanc
prior
exposur
given
pathogen
predispos
host
sever
diseas
manifest
upon
reinfect
propos
case
dengu
viru
earlier
vaccin
develop
effort
inadvert
led
sever
advers
event
follow
infect
target
pathogen
respiratori
syncyti
viru
rsv
case
advers
event
follow
secondari
immun
exposur
believ
result
immunopatholog
respons
result
natur
immun
respons
elicit
initi
exposur
pathogenderiv
antigen
either
infect
vaccin
given
mechan
underli
immunopatholog
process
incomplet
understood
develop
vaccin
highli
immunogen
similarli
inclin
elicit
immunemedi
advers
consequ
repres
substanti
challeng
especi
given
high
expect
vaccin
safeti
addit
immunolog
relat
challeng
relat
observ
certain
organ
encod
antigen
resembl
constitu
human
host
exampl
case
neisseria
meningitidi
group
b
bacteri
polysaccharid
resembl
found
certain
human
cell
lineag
thu
rais
concern
whether
polysaccharidebas
vaccin
success
develop
group
b
n
meningitidi
might
yield
undesir
autoimmun
respons
addit
distinct
import
practic
barrier
new
vaccin
develop
relat
prevent
diseas
threat
pregnant
women
offspr
immun
pregnant
woman
might
abl
protect
neonat
although
number
inactiv
vaccin
either
routin
recommend
use
pregnant
women
eg
inactiv
influenza
vaccin
use
pregnant
women
preor
postexposur
prophylaxi
risk
infect
eg
inactiv
hepat
vaccin
recombin
hbsag
vaccin
develop
new
vaccin
specif
use
pregnant
women
studi
new
vaccin
pregnant
women
imped
concern
aris
potenti
litig
might
follow
appear
congenit
abnorm
child
born
mother
vaccin
pregnant
given
preval
congenit
abnorm
practic
difficulti
prove
safeti
new
vaccin
specif
administ
pregnant
women
current
litigi
environ
surround
vaccin
develop
new
vaccin
address
import
infect
pregnant
women
neonat
eg
group
b
streptococcu
gb
face
signific
challeng
howev
recent
strengthen
recommend
vaccin
pregnant
women
influenza
vaccin
compel
evid
benefit
may
help
foster
increas
attent
overcom
exist
obstacl
develop
appropri
use
vaccin
pregnant
women
remain
number
import
infecti
diseas
effect
prevent
vaccin
exist
list
major
miss
vaccin
comment
yet
avail
highlight
major
approach
current
explor
develop
given
import
season
influenza
seriou
frustratingli
unpredict
global
health
threat
concern
potenti
emerg
highli
virul
pandem
strain
influenza
question
rather
whether
tremend
effort
devot
develop
novel
strategi
product
influenza
vaccin
significantli
improv
upon
limit
influenza
vaccin
current
use
current
research
develop
effort
focus
deriv
flu
vaccin
approach
would
much
greater
speed
reliabl
product
soon
recognit
emerg
new
strain
would
readili
produc
scale
enabl
global
access
would
engend
increas
breadth
coverag
protect
divers
influenza
strain
would
immunogen
efficaci
vulner
popul
elderli
often
respond
poorli
current
avail
vaccin
addit
effort
develop
novel
influenza
vaccin
effort
increas
immunogen
flu
vaccin
popul
typic
respond
poorli
includ
elderli
accomplish
dosespar
benefit
would
use
pandem
set
vaccin
suppli
limit
vaccin
via
use
novel
adjuv
altern
deliveri
approach
intraderm
administr
activ
explor
influenza
viru
first
isol
character
earli
group
work
parallel
uk
us
demonstr
influenza
viru
could
grow
product
minc
chick
embryo
tissu
embryon
hen
egg
viru
could
collect
allanto
fluid
shortli
thereaft
origin
approach
influenza
vaccin
product
develop
involv
chemic
inactiv
viru
formalin
follow
disrupt
detergentyield
noninfecti
immunogen
viral
fragment
current
deploy
influenza
vaccin
continu
manufactur
accord
year
old
process
recent
base
recognit
influenza
viru
also
grow
well
certain
cultiv
mammalian
cell
vaccin
manufactur
look
toward
somewhat
control
method
produc
viru
inactiv
tradit
method
late
russia
earli
michigan
two
group
develop
attenu
liveinfluenza
vaccin
refer
live
attenu
influenza
vaccin
laiv
select
grow
low
temperatur
nasopharynx
higher
temperatur
lung
result
abl
engend
protect
immun
without
diseas
vaccin
current
produc
egg
influenza
virus
vaccin
made
protect
influenza
type
character
serotyp
two
major
surfac
antigen
hemagglutinin
ha
neuraminidas
na
type
b
influenza
virus
yet
similar
serotyp
system
share
gener
structur
type
virus
given
segment
genom
viru
rel
lowfidel
replic
system
influenza
virus
mutat
swap
gene
segment
effici
requir
constant
worldwid
viru
surveil
annual
updat
vaccin
compon
base
surveil
data
vaccin
product
strain
produc
revers
genet
shown
fig
rather
classic
coinfect
select
method
either
way
goal
make
vaccin
virus
display
relev
ha
na
antigen
recent
influenza
vaccin
campaign
larg
target
person
year
age
peopl
immunocompromis
medic
condit
vaccin
describ
work
well
younger
healthi
person
immunogen
drop
sharpli
year
age
numer
effort
make
vaccin
perform
better
older
popul
current
strategi
includ
higher
dose
flu
antigen
inclus
adjuv
base
oilwat
emuls
formul
exist
vaccin
well
explor
novel
potent
adjuv
see
late
multipl
outbreak
avian
influenza
flu
lineag
poultri
market
china
later
viet
nam
indonesia
numer
lethal
primari
infect
human
contact
infect
chicken
lead
great
concern
spread
type
virus
human
human
rare
detect
immun
virus
prompt
numer
program
increas
capac
make
influenza
vaccin
rapidli
order
curtail
prevent
novel
influenza
pandem
april
larg
unexpect
number
case
influenza
emerg
mexico
offseason
mexican
us
cdc
author
quickli
isol
viru
respons
initi
outbreak
show
unusu
constel
human
swine
avian
gene
segment
novel
strain
quickli
spread
becom
global
pandem
vaccin
product
began
soon
initi
recognit
new
flu
strain
octob
vaccin
deliveri
began
unfortun
result
difficulti
produc
vaccin
strain
egg
major
vaccin
produc
arriv
late
octob
peak
viru
circul
alreadi
pass
leav
million
dose
wast
consequ
experi
renew
interest
modern
effici
influenza
vaccin
perform
well
target
popul
given
need
updat
composit
flu
vaccin
research
attent
turn
conserv
antigen
might
provid
broad
protect
rang
influenza
strain
target
type
univers
vaccin
includ
ion
channel
ectodomain
present
type
virus
nucleoprotein
cytotox
tcell
antigen
cleavag
site
stalk
ha
molecul
conserv
ha
stalk
structur
fusion
intermedi
major
ratelimit
element
influenza
vaccin
product
rate
growth
influenza
viru
either
egg
cell
sever
laboratori
develop
method
make
ha
recombin
dna
base
system
thu
bypass
need
grow
viru
egg
cultur
cell
line
advanc
method
includ
bacteria
insect
cell
tobacco
plant
comprehens
spreadsheet
track
progress
pandem
influenza
vaccin
develop
found
websit
http
wwwwhointvacciner
searchdiseasesinfluenzaflutrialstablesenindexhtml
end
estim
million
peopl
worldwid
live
hiv
infect
preced
year
approxim
million
peopl
becam
newli
infect
approxim
million
individu
die
aid
promis
biomed
intervent
contain
aid
pandem
develop
hiv
vaccin
top
global
health
prioriti
yet
hiv
infect
repres
vex
challeng
vaccin
develop
hiv
establish
chronic
persist
infect
clear
host
immun
respons
follow
infect
target
cell
genom
hiva
retrovirusi
transcrib
dna
copi
via
action
revers
transcriptas
newli
form
dna
copi
hiv
genom
integr
host
cell
chromosom
refer
proviru
requisit
step
viral
lifecycl
integr
chromosom
infect
cell
hiv
proviru
altern
activ
transcrib
lead
synthesi
viral
mrna
subsequ
product
new
viru
particl
remain
transcript
silent
function
latent
state
small
percentag
infect
cell
infect
cell
harbor
latent
hiv
provirus
produc
hiv
protein
antigen
recogn
host
antivir
immun
respons
therebi
persist
undetect
upon
subsequ
activ
latent
infect
cell
later
time
viral
rna
transcript
coincid
activ
lead
product
progeni
virion
hiv
target
activ
cell
infect
consequ
deplet
host
abil
mount
hivspecif
nonhivspecif
immun
respons
progress
impair
abil
host
clear
hiv
infect
complic
extens
genet
divers
viru
popul
emerg
progress
diverg
within
infect
individu
function
replic
cycl
accomplish
inher
errorpron
revers
transcriptas
numer
cycl
replic
occur
infect
individu
result
influenc
genet
divers
part
ten
prevent
therapi
immunolog
diseas
popul
hiv
variant
establish
infect
person
facilit
outgrowth
genet
variant
escap
select
pressuresb
effect
host
cellular
humor
immun
respons
inhibitori
effect
antiretrovir
drug
extraordinari
degre
genet
divers
also
manifest
hiv
variant
seen
differ
individu
differ
geograph
region
success
vaccin
infecti
agent
histor
protect
pathogen
exhibit
limit
genet
divers
hiv
repres
unpreced
challeng
vaccin
develop
mani
success
vaccin
protect
viral
infect
predic
induct
neutral
antibodi
respons
viral
surfac
protein
mediat
attach
entri
target
cell
signific
effort
focus
potenti
hiv
surfac
envelop
env
glycoprotein
elicit
infectionneutr
antibodi
unfortun
hiv
highli
resist
neutral
action
antibodi
virtu
heavi
glycosyl
nativ
conform
shield
function
critic
structur
domain
antibodi
bind
result
candid
vaccin
date
fail
elicit
meaning
level
neutral
antibodi
immun
human
volunt
protect
hiv
infect
two
larg
phase
iii
studi
given
inabl
date
candid
hiv
envbas
vaccin
elicit
appreci
level
neutral
antibodi
failur
initi
phase
iii
studi
vaccin
vaccin
strategi
subsequ
becam
larg
focus
induct
cytotox
tcell
respons
constrain
conserv
antigen
gag
pol
nef
hypothes
induct
high
level
hivspecif
tcell
respons
prior
infect
may
prevent
infect
may
enabl
infect
individu
control
viru
replic
better
hypothesi
valid
individu
immun
vaccin
may
exhibit
lower
level
ongo
hiv
replic
progress
aid
slowli
potenti
less
like
transmit
hiv
infect
other
much
work
target
elicit
cell
respons
hiv
involv
vector
gene
deliveri
system
adenovir
vector
describ
howev
result
first
phase
iib
test
concept
studi
step
studi
examin
hypothesi
fail
demonstr
benefici
effect
either
prevent
infect
reduct
viral
load
among
volunt
receiv
vaccin
despit
induct
appreci
level
hivspecif
ctl
respons
recombin
adenovirusbas
vaccin
employ
accompani
suggest
increas
risk
hiv
acquisit
uncircumcis
men
evid
prior
infect
studi
result
refut
ctl
hypothesi
repres
signific
disappoint
aid
vaccin
research
effort
rais
import
question
abil
vaccineelicit
cell
mediat
immun
respons
favor
alter
outcom
hiv
infect
test
concept
studi
progress
phase
iii
studi
thailand
studi
way
vaccin
base
prime
canarypox
vector
alvac
encod
gagpolrevnef
antigen
follow
boost
recombin
env
glycoprotein
yield
approxim
reduct
infect
vaccin
impact
level
postinfect
viral
load
level
vaccin
efficaci
studi
quit
modest
appear
diminish
time
realiz
even
modest
protect
effect
unexpect
given
immunogen
use
elicit
neutral
antibodi
fail
deliv
alon
two
previou
efficaci
trial
alvachiv
vector
found
elicit
low
level
cellular
immun
respons
immun
volunt
date
clear
correl
protect
immun
respons
identifi
studi
result
rais
possibl
protect
effect
nonneutr
antibodi
preponder
igg
antibodi
iga
effort
current
underway
initi
addit
trial
seek
replic
result
studi
help
identifi
potenti
correl
protect
region
world
greater
degre
viral
genet
divers
seen
incid
rate
hiv
infect
higher
altern
approach
seek
elicit
humor
even
neutral
immun
respons
cellular
immun
respons
use
viral
vector
rare
serotyp
adenovirus
also
advanc
toward
proofofconcept
clinic
trial
also
effort
way
util
recent
solv
threedimension
structur
hiv
env
glycoprotein
guid
deriv
nonn
structur
might
serv
better
immunogen
elicit
broadli
crossreact
neutral
antibodi
addit
rel
conserv
function
essenti
sequenc
extracellular
domain
hiv
transmembran
env
protein
explor
immunogen
elicit
broadli
neutral
antibodi
recent
deriv
potent
broadli
neutral
monoclon
antibodi
molecular
clone
gene
encod
hivinfect
individu
demonstr
antibodi
neutral
divers
hiv
strain
may
possibl
howev
remain
unclear
whether
potent
broadli
neutral
antibodi
might
elicit
human
vaccin
defin
hiv
immunogen
challeng
repres
fundament
goal
next
stage
hiv
vaccin
develop
effort
malaria
world
common
vectorborn
diseaseestim
caus
approxim
million
clinic
case
death
annual
diseas
hit
hardest
africa
especi
sever
children
year
age
addit
direct
morbid
mortal
malaria
respons
debilit
ill
enorm
social
econom
consequ
four
malariaassoci
protozo
speci
plasmodium
flaciparum
p
vivax
repres
two
major
agent
parasit
threestag
lifecycl
take
place
within
mosquito
liver
blood
infect
host
cycl
larg
distinct
other
immunolog
perspect
result
multipl
strategi
evas
host
immun
respons
parasit
evolv
parasit
replic
proce
high
level
despit
activ
host
immun
respons
either
result
specif
immun
evas
strategi
inabl
infect
human
host
mount
immun
respons
clear
parasit
prior
infect
protect
individu
repeat
subsequ
infect
although
sever
diseas
often
attenu
follow
repeat
infect
mechan
diseas
modul
incomplet
understood
limit
rel
immun
engend
prior
infect
easili
lost
individu
leav
malariaendem
region
limit
impact
durat
host
immun
respons
malaria
parasit
suggest
success
vaccin
strategi
need
far
better
natur
immun
responsesa
high
bar
effort
develop
effect
vaccin
roughli
two
dozen
antigen
clone
test
potenti
vaccin
immunogen
except
result
disappoint
addit
altern
vaccin
approach
base
immun
inject
irradi
genet
attenu
sporozoit
fail
first
larg
scale
test
contrast
one
recombin
antigen
circumsporozoit
csp
antigen
present
fusion
molecul
hbsag
rt
combin
novel
adjuv
formul
demonstr
modest
promis
earli
human
studi
two
excel
review
effort
avail
recent
report
interim
result
larg
phase
iii
studi
rt
vaccin
conduct
children
seven
african
countri
protect
efficaci
malaria
overal
reduct
sever
malaria
final
result
ongo
efficaci
trial
rt
determin
magnitud
protect
safeti
profil
justifi
largescal
implement
effort
ongo
studi
proceed
success
conclus
earliest
registr
guidanc
vaccin
use
might
avail
result
studi
repres
import
advanc
partial
protect
efficaci
rt
vaccin
uncertain
durat
protect
suggest
vaccin
need
one
compon
broader
solut
control
elimin
malaria
proof
concept
rt
seem
support
ongo
studi
absolut
magnitud
efficaci
may
insuffici
standalon
vaccin
futur
malaria
vaccin
develop
effort
like
focu
identif
addit
protect
antigen
express
specif
stage
parasit
lifecycl
includ
combin
vaccin
potenti
novel
adjuv
improv
magnitud
durat
protect
efficaci
vaccineelicit
immun
respons
given
varieti
antigen
potenti
avail
genom
plasmodia
fulli
sequenc
enorm
effort
find
addit
effect
antigen
might
employ
impress
spreadsheet
malaria
vaccin
program
http
www
whointvaccineresearchlinksrainbowenindexhtml
mycobacterium
tuberculosi
intracellular
mycobacteri
pathogen
repres
one
world
common
seriou
infecti
diseas
billion
peopl
believ
harbor
latent
tuberculosi
infect
approxim
million
activ
case
tuberculosi
million
death
occur
year
furthermor
interfac
hiv
infect
attend
immun
system
damag
increas
sever
tuberculosi
infect
increas
infecti
infect
individu
emerg
dissemin
tuberculosi
isol
resist
multipl
antimicrobi
drug
repres
grow
public
health
threat
howev
need
vaccin
prevent
tuberculosi
clear
signific
number
challeng
face
vaccin
develop
effort
individu
infect
tuberculosi
control
acut
phase
mycobacteri
replic
mount
vigor
innat
adapt
immun
respons
infect
howev
infect
often
clear
host
immun
respons
mycobacteria
abl
persist
multipli
within
vacuol
insid
macrophag
longterm
latenc
establish
fibrot
cyst
lung
recrudesc
dissemin
tuberculosi
occur
later
time
number
infect
individu
like
result
wane
host
immun
control
although
abil
tuberculosi
persist
despit
activ
immun
respons
repres
major
challeng
vaccin
develop
fact
individu
contain
clear
tuberculosi
infect
suggest
vaccin
alter
cours
natur
infect
limit
earli
dissemin
decreas
risk
later
recrudesc
could
provid
major
public
health
benefit
effort
develop
vaccin
tuberculosi
date
back
mani
decad
bacil
better
known
bcg
base
mycobacterium
bovi
first
introduc
current
bcg
provid
compon
routin
expand
programm
immun
epi
schedul
administ
signific
major
world
children
although
protect
efficaci
report
miliari
infect
tuberculosi
mening
children
conflict
result
obtain
differ
studi
regard
abil
bcg
protect
pulmonari
tuberculosi
adult
one
explan
overal
limit
efficaci
bcg
emerg
formal
genom
sequenc
studi
disclos
signific
differ
tuberculosi
vaccin
strain
bcg
variabl
result
bcg
efficaci
studi
differ
popul
geographi
may
deriv
variat
geograph
preval
crossreact
mycobacteri
speci
may
confer
partial
protect
fact
bcg
vaccin
use
throughout
world
repres
homogen
preparationwith
root
strain
bcg
wide
distribut
passag
extens
divers
condit
vaccin
effort
tuberculosi
primarili
focus
evalu
specif
mycobacteri
antigen
eg
test
vaccin
anim
model
variabl
success
strategi
advanc
human
clinic
trial
number
antigen
explor
often
deliv
viral
vector
way
boost
protect
efficaci
bcg
individu
previous
vaccin
bcg
result
one
proof
concept
studi
modifi
vaccinia
ankara
mva
vector
encod
tuberculosi
antigen
booster
immun
infant
receiv
bcg
vaccin
slate
avail
late
altern
vaccin
strategi
base
improv
perform
bcg
vaccin
insert
gene
encod
specif
potenti
protect
antigen
normal
lack
addit
develop
auxotroph
mutant
tuberculosi
explor
potenti
immunogen
specif
attenu
live
vaccin
determin
sequenc
tuberculosi
genom
nearli
decad
ago
help
identifi
numer
previous
unknown
gene
product
increas
repertoir
antigen
evalu
abil
induc
protect
immun
respons
pathogen
sequenc
also
use
elucid
virul
determin
therebi
help
guid
effort
attenu
tuberculosi
ration
togeth
influenza
viru
rsv
piv
account
substanti
major
pediatr
upper
respiratori
ill
consequ
acut
otiti
media
varieti
influenza
vaccin
licens
pediatr
use
vaccin
prevent
infect
paromyxovirus
rsv
piv
remain
elus
signific
impedi
vaccin
develop
rsv
piv
trace
back
unanticip
untoward
result
obtain
clinic
studi
inactiv
rsv
vaccin
earli
earlygener
rsv
vaccinesbas
cultur
viru
inactiv
formalinrais
potent
antibodi
respons
immun
children
howev
subsequ
natur
exposur
rsv
vaccin
recipi
exhibit
frequent
part
ten
prevent
therapi
immunolog
diseas
significantli
sever
lower
respiratori
tract
rsv
infect
unimmun
children
similar
phenomenon
also
seen
formalininactiv
measl
vaccin
era
common
immunopatholog
mechan
may
oper
mechan
exacerb
rsv
diseas
earli
inactiv
vaccin
incomplet
understood
suggest
chemic
inactiv
rsv
measl
viru
result
modif
critic
neutral
structur
surfac
virus
therebi
limit
induct
potent
neutral
antibodi
favor
nonneutr
potenti
immunopatholog
antibodi
respons
passiv
protect
rsv
avail
prematur
infant
form
monoclon
antibodi
target
rsv
f
protein
one
viral
envelop
glycoprotein
certain
antirsv
antibodi
respons
clearli
mediat
protect
oppos
deleteri
effect
altern
addit
propos
inactiv
rsv
vaccin
may
preferenti
induc
immun
respons
respons
may
need
effect
protect
lower
respiratori
tract
rsv
infect
damag
excel
live
attenu
measl
vaccin
develop
rsv
piv
far
resist
approach
use
measl
mump
member
paramyxovirida
famili
virus
nevertheless
base
success
preced
provid
live
attenu
measl
vaccin
desir
induc
immun
respons
attenu
revers
geneticsengin
rsv
still
consid
promis
approach
howev
stabl
attenu
rsv
difficult
achiev
vaccin
safeti
concern
aris
earlier
chapter
rsv
vaccin
develop
result
cautiou
advanc
clinic
evalu
recent
attempt
launch
develop
hybrid
attenu
recombin
rsvpiv
vaccin
well
develop
recombin
protein
base
rsv
vaccin
combin
specif
adjuv
seek
drive
immun
respons
effect
vaccin
meningococcu
serogroup
c
avail
simpl
capsular
polysaccharid
polysaccharid
conjug
protein
carrier
howev
previous
describ
group
b
polysaccharid
share
chemic
similar
shorter
sugar
found
surfac
neuron
tissu
possibl
make
highli
immunogen
conjug
group
b
polysaccharid
theoret
concern
crossreact
self
antigen
imped
develop
type
vaccin
current
work
develop
men
b
vaccin
center
hand
rel
wellconserv
surfac
protein
meningococcu
mani
antigen
identifi
revers
vaccinolog
inde
men
b
vaccin
candid
current
late
stage
clinic
test
may
prove
first
vaccin
licens
discov
use
revers
vaccinolog
method
see
section
antigen
discoveri
addit
combin
acyw
conjug
polysaccharid
vaccin
avail
mani
wealthier
countri
monoval
men
conjug
vaccin
recent
develop
specif
subsaharan
africa
outbreak
group
meningoccu
epidem
common
novel
publicpriv
effort
develop
vaccin
success
target
region
need
effect
men
vaccin
provid
vaccin
low
price
heel
success
novel
mengingococc
serogroup
x
rare
speci
emerg
new
strain
preval
similar
serogroup
intercountri
support
team
http
wwwwhoint
address
challeng
second
independ
vaccin
develop
effort
initi
gb
common
compon
flora
femal
genit
tract
transfer
neonat
caus
sever
infect
fatal
seriou
sequela
shortcours
intrapartum
antibiot
recommend
cultureposit
women
approach
cut
incid
neonat
infect
twothird
thu
reduc
somewhat
urgenc
vaccin
develop
howev
shortcours
antibiot
could
ultim
drive
emerg
antibioticresist
gb
candid
vaccin
shown
elicit
protect
respons
howev
asid
reduc
market
signific
impedi
develop
gb
vaccin
concern
vaccin
pregnant
women
women
childbear
age
birth
defect
might
attribut
vaccin
litigi
societi
would
problemat
vaccin
produc
prior
advent
effect
polymeras
chain
reaction
method
screen
blood
donat
hcv
signific
caus
transfusionrel
hepat
current
transmiss
hcv
among
normal
popul
quit
low
transmiss
among
inject
drug
user
remain
high
hcv
anoth
pathogen
infect
typic
result
immun
respons
elimin
infect
howev
minor
hcv
patient
spontan
clear
infect
suggest
appropri
immun
respons
gener
least
individu
abl
clear
nascent
infect
current
vaccin
work
concentr
vector
gene
deliveri
vaccin
primarili
adenovirus
intend
rais
antivir
cytotox
tcell
respons
howev
recent
success
tremend
ongo
effort
develop
oral
antivir
drug
abl
control
clear
hcv
infect
potenti
interferonfre
regimen
may
decreas
public
health
need
well
limit
scientif
momentum
commerci
impetu
develop
hcv
vaccin
except
live
attenu
varicellazost
viru
vzv
vaccin
use
primari
prevent
chickenpox
reactiv
latent
vzv
infect
caus
shingl
postherpet
neuralgia
older
individu
vaccin
avail
use
human
prevent
infect
member
herp
viru
famili
hsv
type
caus
recurr
vesicular
erupt
belt
respect
like
herp
virus
hsv
infect
clear
immun
system
viru
persist
remain
latent
state
function
inaccess
immun
recognit
clearanc
addit
like
herp
virus
hsv
encod
number
gene
product
promot
evas
host
immun
respons
chapter
recent
attempt
make
vaccin
use
viru
glycoprotein
particularli
glycoprotein
gd
produc
recombin
dna
method
earlier
clinic
efficaci
trial
approach
show
partial
protect
women
vaccin
men
seroneg
reason
curiou
result
clear
howev
result
subsequ
clinic
trial
adjuv
gd
vaccin
recent
demonstr
inabl
vaccin
protect
women
infect
diseas
contrast
earlier
result
although
modest
protect
efficaci
report
infect
addit
recombin
gdbase
approach
number
preclin
studi
explor
abil
cellmedi
immun
respons
hsv
antigen
induc
recombin
vaccin
vector
eg
adenovirus
see
novel
vaccin
vector
prevent
amelior
hsv
infect
genet
engin
attenu
hsv
variant
also
studi
experiment
anim
model
clear
whether
new
strategi
advanc
clinic
evalu
human
anoth
herp
viru
cmv
common
infect
human
individu
infect
adulthood
cmv
caus
sever
infect
neonat
caus
debilit
neurolog
sequela
follow
initi
infect
cmv
persist
infect
human
despit
fact
anticmv
antibodi
present
sizeabl
proport
overal
host
immun
respons
specif
cmv
antigen
ongo
viru
persist
replic
face
activ
host
immun
respons
like
explain
cmv
sophist
repertoir
host
immun
evas
function
includ
inhibit
antigen
present
mechan
immun
effector
respons
chapter
reason
success
vaccin
develop
effort
need
elicit
immun
respons
significantli
effect
quantit
impress
function
limit
immun
respons
gener
cours
natur
cmv
infectionsunless
prove
abl
prevent
initi
cmv
infect
live
attenu
vaccin
investig
sporad
sinc
attenu
strain
town
strain
show
effect
judg
insuffici
immunogen
hybrid
attenu
town
strain
virul
toledo
strain
remain
develop
note
recent
phase
ii
studi
recombin
cmv
glycoprotein
b
subunit
antigen
combin
adjuv
seroneg
women
childbear
age
provid
promis
proof
concept
cmv
vaccin
develop
demonstr
vaccin
efficaci
primari
endpoint
time
cmv
infect
women
result
encourag
unclear
prevent
infect
women
consid
accept
basi
licensur
cmv
vaccin
ultim
intend
protect
congenit
cmv
diseas
offspr
regulatori
author
phase
iii
efficaci
trial
demonstr
success
prevent
congenit
cmv
infect
would
need
significantli
larger
recent
report
proof
concept
studi
demonstr
protect
congenit
cmv
diseas
even
larger
altern
cmv
vaccin
strategi
current
preclin
develop
includ
recombin
dna
rdna
deriv
protein
via
either
dna
vaccin
approach
recombin
viral
vector
attenu
poxvir
vector
ebv
herp
viru
repres
caus
agent
infecti
mononucleosi
widespread
among
human
popul
concert
incomplet
understood
environment
perhap
addit
host
factor
ebv
also
etiolog
associ
burkitt
lymphoma
abil
ebv
establish
persist
infect
human
along
latent
infect
cellular
level
despit
readili
detect
antivir
immun
respons
suggest
like
herp
virus
develop
effect
ebv
vaccin
like
challeng
ebv
vaccin
develop
sinc
coat
protein
common
vaccin
antigen
studi
dengu
fever
viru
mosquitoborn
flaviviru
viru
famili
includ
japanes
enceph
viru
yellow
fever
viru
yfv
success
vaccin
exist
dengu
viru
endem
substanti
portion
tropic
subtrop
area
caus
febril
diseas
well
hemorrhag
fever
four
distinct
serotyp
dengu
fever
viru
prior
infect
one
serotyp
implic
predispos
sever
diseas
follow
infect
second
dengu
fever
viru
serotyp
although
evid
support
concept
question
underli
pathogen
mechan
incomplet
understood
one
hypothesi
propos
antibodi
initi
infect
serotyp
bind
surfac
viru
particl
novel
infect
serotyp
neutral
infect
process
refer
immun
enhanc
infect
still
infecti
complex
antibodyviru
particl
envis
preferenti
taken
cell
reticuloendotheli
system
repres
primari
target
cell
viru
replic
although
verac
hypothesi
establish
present
theoret
concern
type
antibodi
respons
need
induc
vaccin
exert
benefici
rather
detriment
effect
gener
belief
vaccin
elicit
equival
magnitud
durat
immun
respons
four
serotyp
requir
vaccin
base
inactiv
viru
engin
chimer
virus
base
yellow
fever
viru
vaccin
platform
engin
delet
mutant
virus
rdnaderiv
protein
variou
stage
develop
advanc
vaccin
candid
phase
iii
clinic
studi
base
four
recombin
yellow
fever
vaccin
viru
genom
carri
gene
encod
surfac
protein
four
serotyp
dengu
fever
viru
place
nativ
yfv
gene
uptod
review
dengu
fever
vaccin
effort
avail
staphylococcu
aureu
infect
becom
major
public
health
threat
speci
continu
acquir
resist
multipl
antibiot
need
driven
develop
sever
new
vaccin
aureu
infect
one
approach
base
essenti
iron
bind
protein
base
clump
factor
iron
bind
protein
antigen
identifi
via
revers
vaccinolog
approach
shown
promis
preclin
studi
base
preclin
result
phase
iiiii
clinic
trial
initi
evalu
abil
vaccin
candid
prevent
infecti
complic
follow
surgeri
due
aureu
earli
sponsor
vaccin
trial
termin
studi
base
upon
data
indic
vaccin
unlik
demonstr
statist
signific
clinic
benefit
result
new
approach
develop
safe
efficaci
vaccin
aureu
infect
need
clostridium
difficil
gramposit
sporeform
rodshap
bacterium
caus
grow
number
case
sever
diarrhea
coliti
primarili
hospit
patient
long
term
care
resid
diseas
typic
trigger
antibiot
treatment
number
reason
result
turnov
gut
flora
subsequ
overgrowth
c
difficil
case
membran
overgrowth
establish
c
difficil
difficult
clear
vaccin
base
two
high
molecular
weight
toxin
secret
bacterium
earli
clinic
trial
new
antigen
discoveri
method
histor
vaccin
antigen
discov
liter
sens
rather
whole
organ
inactiv
either
heat
chemistri
organ
attenu
forc
growth
nonphysiolog
condit
entir
antigen
repertoir
organ
deliv
immun
system
isol
tetanu
diphtheria
pertussi
toxin
along
chemic
detoxif
scheme
allow
product
refin
vaccin
isol
purif
polysaccharid
capsul
rang
import
bacteri
pathogen
enabl
develop
addit
vaccin
advent
molecular
biolog
late
new
set
tool
allow
direct
approach
discoveri
pathogen
virul
factor
vaccin
antigen
discoveri
vaccin
develop
tool
molecular
biolog
allowedth
develop
vaccin
pathogen
could
propag
cultur
includ
success
develop
recombin
hbv
hpv
vaccin
develop
vaccin
enabl
clinic
anim
model
studi
show
antibodi
direct
specif
viral
target
antigen
eg
hbv
surfac
antigen
hpv
protein
implic
protect
addit
molecular
biolog
approach
enabl
deriv
fulli
recombin
vaccin
antigen
develop
use
limit
set
defin
antigen
bordetella
pertussi
includ
genet
modifi
version
bacteri
toxin
maintain
proper
antigen
structur
longer
toxic
howev
mani
pathogen
vaccin
current
exist
applic
recombin
dna
technologyen
strategi
insuffici
due
incomplet
understand
pathogen
antigen
would
elicit
protect
host
immun
respons
develop
addit
techniqu
discov
protect
antigen
need
fortun
sever
import
technolog
advanc
facilit
discoveri
previous
unknown
protect
antigen
even
complex
microorgan
open
new
era
vaccin
develop
earliest
rdna
technologyen
method
antigen
discoveri
involv
express
individu
pathogenderiv
gene
product
fragment
thereof
bacteri
host
typic
escherichia
coli
use
rdna
express
vector
genom
pathogen
broken
fragment
insert
plasmid
viral
vector
typic
lambda
bacteriophag
coloni
plaqu
spread
membran
allow
grow
hope
express
clone
gene
fragment
abil
recombin
gene
product
react
antibodi
present
serum
individu
recov
infect
pathogen
could
directli
assess
antibodi
present
immun
sera
assess
abil
identifi
antigen
immunochem
reactiv
way
entir
genom
given
pathogen
could
scan
potenti
immunoreact
reactiv
would
indic
vivo
express
gene
product
well
document
antigen
howev
addit
studi
need
demonstr
whether
antibodi
respons
newli
defin
antigen
protect
potenti
document
abil
antigen
elicit
protect
immun
respons
necessari
immun
experiment
anim
commonli
mice
follow
experiment
pathogen
challeng
evalu
infect
outcom
immun
versu
nonimmun
anim
approach
often
use
identifi
antigen
recogn
host
humor
respons
sera
anim
immun
candid
antigen
transfer
host
provid
evid
antibodi
respons
antigen
repres
relev
agent
immun
protect
recent
dna
sequenc
becam
effici
scalabl
determin
entir
sequenc
genom
virus
bacteria
parasit
becom
routin
allow
identif
previous
unknown
gene
predict
gene
product
evalu
vaccin
immunogen
scan
entir
pathogen
genom
via
comput
program
gene
exhibit
specif
characterist
identifi
eg
predict
express
cell
surfac
virtu
possess
leader
sequenc
secret
membran
anchor
sequenc
addit
rel
conserv
gene
within
pathogen
popul
determin
assess
gene
sequenc
multipl
distinct
isol
potenti
vaccin
antigen
identifi
candid
gene
express
appropri
rdna
system
protein
product
test
anim
model
first
bacteri
genom
sequenc
entireti
haemophilu
influenza
mark
begin
new
approach
vaccin
antigen
discoveri
sinc
initi
bacteri
genom
sequenc
determin
genom
sequenc
pathogen
advanc
exponenti
bacteri
genom
sequenc
hundr
current
process
genomebas
antigen
discoveri
appli
wide
rang
bacteria
includ
streptococci
pneumococci
staphylococci
chlamydia
well
nonbacteri
pathogen
plasmodium
falciparum
gener
techniqu
call
revers
vaccinolog
fig
altern
complementari
promis
approach
novel
antigen
discoveri
built
technolog
advanc
proteom
advanc
includ
develop
highresolut
twodimension
gel
electrophoresi
mass
spectrometri
enabl
separ
identif
purif
individu
protein
complex
mixtur
pathogen
protein
proteom
analys
small
cultur
bacteria
prefer
taken
directli
infect
person
otherwis
grown
physiolog
similar
condit
subject
physic
enzymat
treatment
specif
proteas
gener
peptid
fragment
fraction
microhighperform
liquid
chromatographi
sequenc
molecular
spectrometri
overlap
set
peptid
approxim
amino
acid
suffici
identifi
antigen
provid
mean
find
gene
combin
proteom
serolog
method
select
potenti
novel
vaccin
immunogen
call
serolog
proteom
analysi
serpa
use
screen
pathogen
proteom
express
protein
recogn
antibodi
present
sera
obtain
individu
recov
infect
pathogen
process
vaccin
develop
chang
significantli
recent
yearsa
process
facilit
improv
understand
human
immun
system
function
well
advent
power
new
technolog
vaccin
develop
vaccin
develop
therefor
commonli
pursu
hypothesisdriven
manner
howev
time
infecti
diseas
effect
vaccin
current
exist
repres
challeng
target
furthermor
global
chang
influenc
emerg
rate
spread
infecti
diseas
place
unpreced
challeng
product
pace
new
vaccin
develop
current
opportun
improv
understand
human
immunolog
includ
biolog
innat
immun
system
function
antigen
present
gener
mainten
tand
bcell
memori
improv
technolog
measur
human
cellular
humor
immun
respons
advent
genom
proteom
technolog
new
antigen
discoveri
wealth
recombin
dna
methodolog
enabl
isol
protect
antigen
divers
pathogen
deriv
novel
vaccin
vector
elicit
immun
respons
pathogenderiv
antigen
develop
recombin
synthet
approach
largescal
product
precis
defin
vaccin
antigen
includ
abil
produc
immunogen
accur
recapitul
conform
structur
nativ
antigen
altern
alter
serv
effect
immunogen
develop
synthet
consensu
antigen
abl
elicit
broader
immun
respons
would
sequenc
obtain
individu
isol
highli
divers
pathogen
eg
hiv
influenza
emerg
new
mechanismbas
adjuv
enhanc
immunogen
vaccin
antigen
use
novel
method
shift
rel
immunodomin
specif
pathogen
gene
product
increas
immunogen
conserv
antigen
otherwis
divers
pathogen
genom
typic
poorli
immunogen
cours
natur
infect
current
challeng
need
develop
vaccin
infect
natur
immun
often
ever
develop
follow
natur
infect
eg
hiv
malaria
hepat
c
need
develop
vaccin
protect
genet
divers
pathogen
variant
limit
number
vaccin
immunogen
eg
hiv
malaria
influenza
need
develop
vaccin
infect
concern
exist
vaccin
elicit
potenti
autoimmun
neisseria
meningid
group
b
immunopatholog
eg
rsv
respons
challeng
respond
rapidli
effect
power
new
technolog
newli
emerg
infectionsinclud
nt
seen
human
eg
sar
novel
antigen
variant
anticip
predict
eg
pandem
influenza
maxim
valu
innov
new
approach
ensur
safeti
new
vaccin
deriv
proteom
approach
antigen
discoveri
appli
identifi
novel
vaccin
candid
number
human
pathogen
includ
helicobact
pylori
chlamydia
pneumonia
staphylococcu
aureu
bacillu
anthraci
haemophilu
influenza
neisseria
meningitidi
group
b
plasmodium
falciparum
vaccin
candid
n
meningitidi
group
b
vaccin
late
stage
clinic
evalu
success
provid
first
success
exampl
vaccin
antigen
discov
method
revers
vaccinolog
new
genom
method
antigen
discoveri
identifi
gene
encod
candid
antigen
proteom
method
necessari
show
immun
respons
desir
type
rais
protein
addit
necessari
show
immun
respons
elicit
follow
immun
candid
antigen
engend
degre
protect
term
adjuv
deriv
latin
adjuvar
help
refer
substanc
ad
compon
vaccin
preparationin
addit
vaccin
antigen
themselvesthat
improv
immunolog
respons
antigen
adjuv
catchal
term
includ
broad
rang
molecular
entiti
act
via
diverseand
number
instanc
yet
elucidatedpathway
recent
adjuv
deriv
empir
mechan
augment
immun
respons
unknown
result
principl
avail
guid
improv
known
adjuv
develop
new
one
howev
recent
advanc
understand
mechan
dendrit
cell
sens
presenc
pathogen
constitu
translat
inform
shape
quantiti
qualiti
durabl
host
cellular
humor
adapt
immun
respons
transform
adjuv
discoveri
optim
process
trial
error
repres
area
hypothesisdriven
research
mechanismbas
discoveri
particularli
promis
advanc
emerg
discoveri
pathogen
sens
innat
immun
system
mediat
recognit
specif
pathogenassoci
molecular
pattern
pamp
pathogen
recognit
receptor
prr
tolllik
receptor
tlr
express
dendrit
cell
dc
hematolymphoid
epitheli
cell
chapter
pathogenderiv
pamp
recogn
tlr
consist
structur
found
pathogen
includ
bacteria
virus
parasit
part
normal
vertebr
biolog
follow
bind
specif
pamp
specif
prr
specif
cellular
activ
respons
cascad
trigger
directli
confront
intrud
pathogen
andor
lead
activ
specif
host
adapt
immun
respons
mechan
breakthrough
basic
immunolog
readili
translat
consid
scienc
adjuv
biolog
progress
occur
especi
opportun
time
new
vaccin
develop
strategi
transit
tradit
approach
use
attenu
kill
pathogen
highli
defin
purifi
recombin
protein
socal
subunit
vaccin
nonrepl
vector
antigen
although
newer
approach
promis
perspect
vaccin
safeti
opportun
afford
design
structur
vaccin
immunogen
recombin
synthet
vaccin
often
inher
less
immunogen
tradit
vaccin
base
attenu
live
virus
intact
kill
organ
context
current
vaccin
develop
part
ten
prevent
therapi
immunolog
diseas
regulatori
approv
process
adjuv
develop
part
vaccin
independ
product
consequ
current
adjuv
licens
regulatori
author
standalon
product
contemporari
effort
develop
novel
adjuv
focus
target
activ
tlr
express
specif
cell
critic
gener
innat
adapt
host
respons
specif
pathogen
famili
consist
distinct
tlr
identifi
date
human
chapter
tlr
express
number
innat
immun
cell
includ
dc
macrophag
neutrophil
endotheli
cell
fibroblast
given
import
dc
critic
antigenpres
cell
studi
biolog
tlr
signal
focus
cell
differ
tlr
express
distinct
subpopul
dc
depend
tlr
distinct
cellular
compart
tlr
express
surfac
human
myeloid
dc
includ
heterodimer
tlr
well
tlr
fig
cell
express
tlr
within
endoplasm
reticulum
er
phagolysosom
plasmacytoid
dc
pdc
express
within
erphagolysosom
tlr
express
cell
surfac
primarili
activ
pamp
encount
extracellular
environ
tlr
express
erphagolysosom
activ
pamp
includ
viral
pathogenderiv
rna
dna
tend
rout
endosom
compart
activ
tlr
innat
immun
cell
lead
product
specif
cytokin
well
express
costimulatori
molecul
lead
induct
adapt
immun
respons
given
differ
dc
express
differ
tlr
signal
via
differ
tlr
result
express
distinct
pattern
cytokin
believ
activ
specif
tlr
various
favor
induct
immun
respons
differenti
augment
either
direct
crosspresent
pathway
antigen
present
fig
although
data
induct
specif
type
immun
respons
engag
specif
tlr
emerg
murin
studi
yet
valid
human
abil
tailor
adjuv
prepar
achiev
desir
type
immun
respons
specif
vaccin
immunogen
promis
notion
natur
occur
ligand
tlr
includ
lipopolysaccharid
lp
bacteri
cell
wall
recogn
triacyl
lipopeptid
recogn
tlr
diacyl
lipopeptid
recogn
tlr
peptidoglycan
recogn
flagellin
monom
make
flagella
recogn
singlestrand
rna
recogn
doublestrand
rna
recogn
unmethyl
dna
contain
dinucleotid
pair
cpg
recogn
base
insight
varieti
approach
develop
adjuv
predic
activ
specif
tlr
pathway
activ
pursu
one
interest
aspect
adjuv
develop
reveal
mechan
action
adjuv
origin
identifi
via
process
trial
error
well
delin
import
aspect
certain
empir
deriv
vaccin
abl
induc
highlevel
longlast
immun
respons
illustr
exampl
complet
freund
adjuv
cfa
long
serv
benchmark
laboratori
studi
adjuv
cfa
mix
emuls
miner
oil
mannid
monool
kill
mycobacteria
howev
far
reactogen
use
human
caus
signific
pain
fig
genom
bacterium
scan
algorithm
identifi
gene
open
read
frame
individu
gene
analyz
presenc
put
structur
present
surfac
bacterium
membran
anchor
certain
type
secret
signal
etc
could
vaccin
target
upper
two
draw
mani
case
initi
candid
gene
rescan
genom
altern
isol
speci
order
identifi
conserv
surfac
antigen
candid
gene
satisfi
criteria
express
recombin
protein
use
vaccin
anim
antigen
rais
desir
immun
respons
taken
forward
develop
parallel
proteom
exercis
may
carri
confirm
presenc
select
antigen
surfac
bacterium
prefer
taken
patient
sampl
minim
vitro
cultur
lower
two
draw
bacterium
treat
proteas
mixtur
cleav
surfac
protein
cleavag
product
collect
analyz
mass
spectrometri
cleavag
product
broken
small
peptid
part
spectrometri
process
sequenc
imput
molecular
weight
compar
predict
sequenc
genom
extra
proteom
step
reduc
number
candid
screen
expens
anim
studi
vaccin
abcess
site
injectionreact
would
exacerb
cfa
use
repeatedli
altern
prepar
term
incomplet
freund
adjuv
ifa
lack
mycobacteri
compon
associ
inject
site
reaction
sever
enough
limit
use
experiment
therapeut
cancer
vaccin
although
cfa
toxic
preclud
use
vaccin
adjuv
human
mani
constitu
includ
liposaccharid
dna
specif
bacteri
cell
wall
compon
understood
exert
adjuv
effect
vaccineinduc
immun
respons
via
engag
specif
tlr
similarli
live
attenu
mycobacterium
bovi
strain
bcg
long
wide
employ
vaccin
prevent
tuberculosi
includ
cell
wall
peptidoglycan
dna
compon
activ
specif
tlr
interestingli
highli
effect
yellow
fever
vaccin
shown
activ
multipl
tlr
part
induct
antivir
immun
respons
one
version
hib
polysaccharid
conjug
vaccin
licens
use
children
prevent
invas
hib
diseas
includ
meningococc
outermembran
protein
complex
ompc
protein
carrier
ompc
conjug
favor
immunogen
properti
correl
abil
ompc
activ
dc
via
major
class
adjuv
avail
develop
includ
alum
liposom
immunestimul
complex
iscom
virosom
emuls
cytokin
tollreceptor
agonist
aluminium
salt
sometim
refer
gener
alum
classic
adjuv
often
use
vaccin
human
includ
rang
salt
aluminum
precipit
basic
condit
usual
aluminum
sulfat
mix
sodium
potassium
hydroxid
plu
variabl
amount
phosphat
composit
alum
use
adjuv
vari
current
avail
vaccin
influenc
vaccin
immunogen
alum
util
adjuv
mani
current
avail
vaccin
compos
inactiv
toxin
recombin
protein
live
attenu
vaccin
includ
alum
adjuv
alum
serv
two
main
purpos
adjuv
first
act
antigen
depot
vaccin
antigen
adsorb
alum
elut
follow
inject
host
second
alum
act
mild
irrit
caus
recruit
leukocyt
necessari
gener
immun
respons
site
inject
adsorpt
antigen
alum
routin
improv
immunogen
particularli
antibodi
respons
alum
typic
enhanc
tcell
respons
alum
compon
mani
vaccin
decad
excel
safeti
record
although
mechan
action
defin
part
ten
prevent
therapi
immunolog
diseas
detail
recent
work
implic
activ
bind
alum
membran
dendrit
cell
dc
result
alter
lipid
membran
structur
key
process
alum
adjuv
effect
new
adjuv
develop
alum
may
remain
compon
combin
adjuv
mixtur
case
newer
adjuv
approach
clinic
use
may
eventu
supplant
agent
effect
provid
depot
local
inflammatori
respons
accentu
host
immun
respons
use
lipid
polar
head
group
eg
triglycerid
differ
type
hydrophob
tail
one
form
either
micel
sphere
multilamellar
sheet
aqueou
environ
right
condit
antigen
incorpor
sphere
layer
sheet
provid
potenti
slowreleas
depot
system
immunopotenti
detoxifi
lp
deriv
monophosphoryl
lipid
mpl
ad
lipid
mix
immunestimul
complex
iscom
repres
proprietari
form
liposom
made
cholesterol
saponin
quillaia
bark
variou
member
qsx
famili
triterpen
glycosid
phospholipid
form
cagelik
structur
antigen
entrap
intercal
iscom
complex
provid
depot
function
well
facilit
deliveri
uptak
process
vaccin
immunogen
apc
purifi
influenza
viru
hemagglutinin
ha
neuraminidas
mix
phosphatidyl
cholin
phosphatidyl
ethanolamin
polar
lipid
form
empti
particl
surfac
properti
influenza
viru
ad
antigen
solut
mix
lipid
result
incorpor
antigen
insid
particl
provid
vehicl
deliv
antigen
interior
cell
via
influenza
ha
membran
fusion
process
therebi
enabl
antigen
process
present
via
major
histocompat
complex
mhc
class
pathway
emuls
numer
oilinwat
waterinoil
emuls
test
adjuv
one
emuls
use
licens
influenza
vaccin
consist
squalan
metaboliz
shark
oil
two
surfact
polyoxyethylen
sorbitan
monool
sorbitan
trioleat
oilinwat
emuls
cytokin
hostproduc
immunomodul
regul
immun
cell
action
chapter
sever
cytokin
test
potenti
vaccin
adjuv
includ
granulocytemacrophag
colonystimul
factor
gmcsf
defin
tlr
agonist
explor
vaccin
adjuv
lp
partial
detoxifi
form
mpl
activ
tlr
thoroughli
explor
clinic
trial
evid
enhanc
abil
increas
percentag
individu
respond
protect
antibodi
level
hepat
b
compar
standard
hepat
b
vaccin
one
hepat
b
vaccin
employ
adjuv
formul
term
consist
combin
alum
mpl
licens
use
highrisk
individu
one
two
licens
hpv
vaccin
also
includ
adjuv
formul
wide
varieti
agonist
consist
oligodeoxynucleotid
contain
unmethyl
cpg
motif
cpgodn
evalu
preclin
studi
cpgodn
resembl
bacteri
dna
modifi
includ
phosphorothio
backbon
increas
stabil
two
cpgodn
adjuv
evalu
recent
phase
ii
trial
shown
increas
time
magnitud
induct
protect
antibodi
level
well
proport
respond
individu
recombin
hbsag
vaccin
one
cpgodn
adjuv
also
elicit
protect
antibodi
respons
immun
hivinfect
individu
previous
fail
respond
hepat
b
vaccin
approach
studi
way
induc
protect
immun
respons
hepat
b
earlier
initi
vaccin
regimen
fewer
dose
vaccin
individu
would
predict
result
specif
chronic
medic
condit
renal
failur
respond
poorli
standard
hepat
b
vaccin
addit
cpgodnbas
adjuv
describ
small
chemic
compound
structur
resembl
nucleic
acid
base
identifi
activ
eg
imiquimod
eg
resiquimod
compound
evalu
vaccin
adjuv
preclin
studi
flagellin
agonist
also
explor
adjuv
recent
attent
also
focus
coupl
tlr
agonist
antigen
rather
mere
mix
togeth
inject
cpg
oligonucleotid
conjug
antigen
test
preclin
studi
hepat
b
vaccin
human
clinic
trial
treatment
allergi
ligand
coupl
hiv
antigen
ligand
flagellin
fuse
varieti
antigen
instanc
coupl
tlr
ligand
antigen
result
substanti
improv
immun
respons
compar
mixturespotenti
result
enabl
antigen
tlr
ligand
coloc
dc
compart
numer
preclin
studi
confirm
mani
natur
synthet
tlr
agonist
possess
adjuv
activ
importantli
earli
human
clinic
trial
tlrpredic
adjuv
support
promis
approach
mechanismbas
strategi
augment
vaccin
immunogen
import
challeng
defin
potent
besttoler
variant
defin
rule
activ
specif
tlr
pathway
might
translat
predict
augment
desir
type
immun
respons
hope
gener
rule
emerg
suggest
increas
number
novel
adjuv
develop
perform
best
type
vaccin
immunogen
result
obtain
specif
type
immunogenadjuv
combin
extrapol
predict
likelihood
enhanc
immunogen
vaccin
howev
import
challeng
remain
primari
challeng
nextgener
adjuv
develop
find
combin
retain
immunopotenti
action
minim
vaccineassoci
advers
experi
shortterm
advers
experi
local
inject
site
reaction
repres
undesir
side
effect
may
disqualifi
candid
adjuv
earli
clinic
develop
given
vaccin
administ
healthi
peopl
prevent
potenti
futur
infecti
diseas
potenti
rarer
advers
experi
autoimmun
may
manifest
much
vaccin
longer
latenc
time
vaccin
adjuv
administr
undoubtedli
import
consider
use
prophylact
vaccin
induct
cellmedi
immun
respons
consid
import
compon
vaccin
strategi
mani
diseas
vaccin
current
avail
mani
caus
intracellular
pathogen
need
develop
safe
readili
scalabl
approach
elicit
durabl
tcell
respons
immun
human
given
critic
role
cell
play
induct
differenti
mainten
tcell
respons
novel
vaccin
strategi
like
also
requir
appropri
tcell
respons
elicit
tcell
respons
foreign
antigen
usual
depend
de
novo
express
antigen
within
host
cell
subsequ
process
present
via
class
mhc
pathway
chapter
novel
vaccin
strategi
predic
need
achiev
synthesi
pathogenderiv
antigen
within
apc
immun
human
host
increas
appreci
role
crosspresent
pathway
play
elicit
class
irestrict
tcell
respons
de
novo
antigen
synthesi
may
need
occur
within
apc
one
mani
attract
attribut
effect
live
attenu
vaccin
abil
recapitul
variou
degre
mani
process
lead
gener
potent
immun
respons
follow
natur
infect
process
includ
fact
replic
virus
depend
gain
access
host
cell
genom
replic
synthesi
essenti
compon
viru
particl
permit
propag
infect
within
host
one
immunolog
benefit
requir
de
novo
synthesi
viral
gene
product
within
infect
cell
provid
key
opportun
viral
antigen
present
via
mhc
class
pathway
elicit
antivir
cellular
immun
respons
along
process
present
intact
viru
protein
via
mhc
class
ii
pathway
lead
product
antivir
antibodi
respons
live
attenu
viral
vaccin
strong
track
record
induct
broad
cellular
humor
immun
respons
howev
despit
track
record
success
like
new
live
attenu
viral
vaccin
deriv
manner
resembl
previou
success
effort
eg
empir
deriv
live
attenu
polio
yellow
fever
varicellazost
vaccin
import
reason
chang
includ
desir
safe
wellcharacter
vaccin
whose
mechan
attenu
defin
monitor
cours
vaccin
product
use
inde
recent
develop
live
attenu
vaccin
deriv
use
new
approach
genet
reassort
fig
although
approach
proven
success
limit
appli
homolog
virus
eg
deriv
viru
type
whose
genom
segment
capabl
readi
genet
reassort
cultur
virus
manipul
revers
genet
respons
desir
produc
vaccin
safe
reliabl
elicit
desir
immun
respons
especi
tcell
respons
sever
approach
explor
develop
novel
vector
system
permit
express
pathogenderiv
antigen
mani
approach
base
virus
distinct
viral
pathogen
target
induct
host
immun
respons
insert
pathogenderiv
gene
product
express
via
recombin
method
heterolog
antigen
altern
nonvir
express
system
dna
vaccin
pathogenderiv
antigen
express
isol
depend
virusmedi
antigen
deliveri
apc
follow
host
inocul
collect
recombin
heterolog
express
system
commonli
refer
vaccin
vector
instanc
recombin
vector
express
specif
antigen
case
dna
vaccin
certain
viral
vector
eg
adenoviru
other
insert
pathogenderiv
antigen
antigen
encod
viral
vector
backbon
express
eg
poxviru
vector
new
approach
employ
express
system
inher
nonrepl
eg
dna
vaccin
employ
viral
vector
replic
high
level
tissu
cultur
vivo
eg
complement
adenoviru
delet
variant
host
rangerestrict
poxvirus
numer
approach
pursu
develop
novel
vaccin
vector
need
meet
certain
common
criteria
emerg
vaccin
approach
applic
widespread
use
particular
success
approach
must
safe
healthi
immunodefici
human
desir
immunogen
includ
individu
may
previous
expos
viru
vector
deriv
eg
vaccinia
adenoviru
abl
produc
larg
quantiti
stabl
manner
sever
novel
vaccin
vector
current
studi
preclin
studi
human
clinic
trial
describ
depend
deliveri
express
candid
pathogenderiv
gene
sequenc
number
way
dna
vaccin
repres
simplest
approach
deliv
pathogenderiv
gene
viral
vector
similarli
serv
deliv
pathogen
gene
sequenc
host
apc
either
directli
indirectli
manner
depend
take
advantag
lifecycl
tropism
viru
adapt
express
exogen
pathogen
gene
product
abil
purifi
plasmid
dna
contain
heterolog
antigen
express
control
eukaryot
transcript
regulatori
rna
process
signal
elicit
immun
respons
inject
experiment
anim
discov
serendipit
howev
sinc
initi
descript
develop
socal
dna
vaccin
becom
activ
area
preclin
clinic
vaccin
develop
reason
enthusiasm
includ
attract
simplic
facil
prepar
vector
encod
defin
antigen
interest
reason
straightforward
method
vaccin
product
inher
stabil
temperatur
avoid
induct
antivector
immun
respons
affect
recombin
viral
vaccin
vector
approach
develop
although
dna
vector
commonli
inject
intramuscularli
gener
specif
immun
respons
depend
uptak
vector
dna
apc
follow
express
process
present
vectorencod
antigen
tissu
tissu
fluid
present
hostil
environ
purifi
dna
process
dna
uptak
apc
appear
rel
ineffici
much
dose
inject
dna
degrad
reach
apc
initi
desir
immun
respons
earli
dna
vaccin
research
pursu
mice
although
studi
perform
numer
anim
speci
recent
studi
usual
util
intramuscular
inject
vaccin
vector
dna
variou
intraderm
transderm
approach
also
explor
murin
part
ten
prevent
therapi
immunolog
diseas
studi
shown
administr
antigenencod
plasmid
dna
elicit
appreci
cellular
humor
immun
respons
confer
protect
experiment
challeng
howev
translat
promis
result
human
proven
frustrat
dna
vaccin
gener
well
toler
immun
volunt
human
studi
dna
vaccin
date
administr
even
substanti
quantiti
dna
vaccin
vector
elicit
rel
lowlevel
immun
respons
yet
known
whether
disappoint
result
reflect
fundament
differ
immunogen
behavior
dna
vaccin
human
mice
fact
dna
dose
administ
human
match
administ
mice
dna
per
weight
immun
host
varieti
approach
explor
prolong
dna
surviv
tissu
promot
effici
target
dna
apc
develop
novel
adjuv
might
specif
amplifi
immun
respons
dna
vaccin
addit
novel
dna
deliveri
approach
situ
electropor
shown
promis
increas
dna
vaccin
immunogen
earli
clinic
studi
human
dna
vaccin
current
use
candid
prevent
vaccin
wide
varieti
infecti
diseas
includ
hiv
tuberculosi
malaria
cmv
poxvirus
repres
famili
virus
physic
largest
virus
possess
largest
genom
much
poxviru
genom
encod
gene
product
serv
evad
host
immun
respons
requir
viru
replic
tissu
cultur
facil
techniqu
insert
delet
specif
viral
gene
develop
abil
accommod
sizeabl
foreign
gene
insert
part
function
larg
size
poxviru
genom
larg
packag
capac
poxviru
virion
result
favor
attribut
poxvirus
util
extens
laboratori
studi
viru
biolog
recombin
protein
product
host
immun
respons
although
poxvirus
encod
multipl
gene
product
help
viru
evad
host
immun
respons
nevertheless
potent
immunogen
studi
individu
immun
decad
ago
vaccinia
viru
cours
smallpox
erad
effort
shown
viru
induc
longlast
memori
tand
bcell
immun
respons
contrast
viral
vector
current
develop
poxvirus
replic
readili
cultur
requir
engin
host
cell
support
propag
ex
vivo
one
import
limit
poxviru
vector
develop
date
given
larg
size
poxviru
genom
multitud
gene
product
natur
express
even
larg
insert
deriv
foreign
pathogen
interest
present
minor
vaccin
vector
antigen
deliv
recogn
host
immun
system
effect
approach
focu
immun
respons
antigen
interest
need
develop
toward
end
varieti
socal
primeboost
approach
explor
host
immun
respons
prime
one
type
recombin
vaccin
vector
dna
vaccin
adenoviru
vector
boost
subsequ
deliveri
poxviru
vector
encod
antigen
manner
immun
respons
antigen
interest
significantli
augment
number
preclin
studi
vaccinia
viru
repres
prototyp
poxviru
vector
viru
one
employ
success
smallpox
erad
campaign
use
laboratori
tool
decad
howev
given
current
high
expect
vaccin
safeti
increas
number
immunodefici
individu
present
popul
origin
vaccinia
strain
use
smallpox
erad
effort
consid
safe
gener
use
howev
studi
vacciniabas
vaccin
vector
provid
strong
basic
foundat
research
highli
attenu
poxviru
variant
modifi
vaccinia
ankara
mva
attenu
vaccinia
viru
origin
deriv
prolong
passag
vaccinia
viru
isol
chicken
embryo
fibroblast
cultur
cours
extens
passag
cultur
viral
variant
emerg
fortuit
delet
larg
section
viral
genom
includ
encod
import
poxviru
immun
evas
gene
determin
abil
viru
replic
cell
obtain
differ
anim
speci
specif
mva
grow
well
chicken
cell
replic
human
cell
cultur
vivo
confer
inher
safeti
featur
mva
safe
administ
individu
high
risk
advers
consequ
vaccinia
immun
toward
end
smallpox
erad
effort
recent
garner
renew
interest
potenti
safer
smallpox
vaccin
wake
concern
bioterror
threat
even
though
mva
replic
mammalian
cell
viru
demonstr
favor
immunogen
properti
mva
use
vector
express
gene
wide
varieti
gene
includ
hiv
tb
malaria
antigen
either
alon
primeboost
regimen
mva
administ
follow
initi
prime
immun
vaccin
vector
case
tb
vaccin
bcg
concert
effort
way
improv
perform
mva
manipul
seri
poxviru
gene
dampen
human
immun
respons
viru
antigen
insert
avipox
famili
poxvirus
infect
bird
caus
respiratori
diseas
poultri
canarypox
member
avipox
group
adapt
vaccin
vector
canarypox
replic
well
avian
cell
cultur
replic
human
cell
cultur
human
vivo
result
canarypox
like
mva
provid
interest
vector
system
inher
safeti
featur
canarypox
vector
commonli
alvac
test
sever
clinic
studi
either
alon
primeboost
regimen
follow
prime
adenoviru
vector
recombin
protein
antigen
inde
alvac
vector
encod
hiv
antigen
provid
prime
immun
boost
recombin
hiv
env
antigen
previous
describ
phase
iii
hiv
vaccin
trial
thailand
date
result
human
clinic
trial
canarypox
vector
disappoint
lowlevel
specif
immun
respons
gener
human
volunt
adenovirus
adenovirus
one
common
caus
upper
respiratori
gastrointestin
infect
seen
extens
use
clinic
trial
one
first
gene
therapi
vector
adenoviru
vector
current
studi
preclin
clinic
set
disabl
delet
earli
gene
necessari
replic
immun
host
adenoviru
vaccin
vector
develop
use
wellcharacter
readili
produc
adenoviru
serotyp
vector
backbon
disabl
adenoviru
vector
grown
cell
express
gene
artifici
insert
cell
genom
disabl
vector
encod
heterolog
pathogenderiv
antigen
interest
enter
vaccin
cell
pathogen
gene
product
express
process
present
host
apc
adenovirus
directli
infect
dendrit
cell
promis
provid
effici
vaccin
vector
robust
antibodi
tcell
respons
heterolog
antigen
gene
express
adenoviru
vector
observ
preclin
anim
model
furthermor
earlyphas
human
clinic
trial
adenoviru
vector
gener
well
toler
proven
effect
recombin
vector
system
studi
date
elicit
highlevel
tcell
respons
main
potenti
drawback
widespread
use
adenoviru
vector
human
depend
adenoviru
type
geograph
locat
variabl
level
preexist
immun
found
human
result
prior
natur
acquir
adenoviru
infect
high
level
antibodi
adenoviru
vector
might
blunt
immunogen
efficaci
adenoviru
vectorbas
vaccin
remain
seen
signific
limit
preexist
immun
adenoviru
vector
deriv
epidemiolog
preval
serotyp
eg
limit
vaccin
immunogen
current
effort
develop
vaccin
vector
base
serotyp
rare
human
popul
novel
adenoviru
vector
specif
design
avoid
preexist
antibodi
respons
may
yield
effect
altern
approach
adenoviru
vector
current
use
clinic
trial
vaccin
hiv
malaria
influenza
rang
pathogen
alphavirus
rna
virus
caus
zoonot
diseas
venezuelan
equin
enceph
virus
normal
circul
human
immun
virus
quit
rare
human
alphavirus
strategi
overexpress
protein
make
virion
make
separ
subgenom
rna
specif
encod
gene
product
current
recombin
alphaviru
vaccin
vector
strategi
take
advantag
subgenom
transcript
replac
viral
gene
select
gene
antigen
maintain
signal
translat
protein
product
addit
use
genet
complement
possibl
gener
viru
particl
contain
heterolog
antigenencod
express
cassett
viru
particl
effici
mediat
infect
host
cell
lack
alphaviru
gene
need
viru
replic
spread
beyond
initi
target
cell
infect
alphaviru
vector
rival
adenovirus
effici
protein
product
tissu
cultur
induc
robust
antibodi
tcell
respons
preclin
studi
one
current
limit
alphaviru
vector
system
difficulti
scale
product
system
howev
technic
matter
address
addit
ampl
safeti
data
need
widespread
use
alphaviru
vaccin
achiev
endors
regulatori
author
use
healthi
popul
adenoassoci
virus
aav
belong
famili
small
singlestrand
dna
virus
parvovirus
includ
parvoviru
caus
rash
children
known
fifth
diseas
measl
mump
rubella
varicella
make
first
four
aav
transmit
conjunct
adenoviru
infect
known
caus
signific
diseas
poorli
immunogen
cours
natur
infect
aav
integr
genom
infect
cell
usual
particular
place
chromosom
although
integr
appear
effici
sitespecif
replicationdefect
adenoassoci
virus
type
develop
vaccin
vector
use
although
encourag
result
report
preclin
studi
phase
studi
human
demonstr
disappoint
immunogen
poor
immun
respons
viru
may
make
aav
less
attract
vaccin
vector
made
good
candid
gene
therapi
wherein
prolong
product
gene
might
accru
without
immun
system
kill
infect
cell
inde
posit
result
recent
report
demonstr
clinic
benefit
individu
hemophilia
b
receiv
aav
vector
encod
human
factor
ix
recent
effort
made
adapt
replicationdefect
aav
encod
neutral
monoclon
antibodi
hiv
novel
strategi
term
vector
immunoprophylaxi
demonstr
promis
abil
protect
human
mice
experiment
challeng
hiv
approach
prove
similarli
effect
human
studi
futur
provid
interest
bridg
previous
distinct
histor
concept
activ
passiv
immun
approach
challeng
optim
full
public
health
potenti
exist
vaccin
larg
relat
programmat
consider
contrast
terribl
impact
infecti
diseas
prevent
vaccin
big
three
killer
hiv
tuberculosi
malaria
pose
direct
challeng
scientif
commun
develop
new
gener
vaccin
overcom
larg
biolog
obstacl
control
elimin
diseas
natur
challeng
pose
pathogen
necessit
futur
vaccin
effort
simpli
recapitul
immun
respons
engend
natur
infect
premis
tradit
vaccin
develop
effort
rather
substanti
improv
upon
develop
vaccin
prevent
infect
sofar
refractori
pathogen
pursu
improv
understand
immun
respons
natur
infect
well
delin
reason
host
immun
respons
fail
either
clear
incipi
infect
prevent
futur
new
one
essenti
fortun
earli
empir
approach
replac
hypothesisdriven
strategi
enabl
improv
insight
function
human
immun
system
well
new
technolog
includ
higherresolut
tool
describ
quantit
pathogenspecif
immun
respons
novel
method
antigen
discoveri
target
optim
immunogen
develop
new
mechanismbas
adjuv
advent
innov
method
vaccin
vectormedi
antigen
deliveri
thu
although
challeng
may
vex
scientif
technic
foundat
vaccin
develop
effort
rest
never
stronger
